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Rates of overdose deaths involving prescription drugs 
increased rapidly in the United States during 1999–2006 (1). 
However, such mortality data do not portray the morbidity asso-
ciated with prescription drug overdoses. Data from emergency 
department (ED) visits can represent this morbidity and can be 
accessed more quickly than mortality data. To better understand 
recent national trends in drug-related morbidity, CDC and the 
Substance Abuse and Mental Health Services Administration 
(SAMHSA) reviewed the most recent 5 years of available data 
(2004–2008) on ED visits involving the nonmedical use of pre-
scription drugs from SAMHSA’s Drug Abuse Warning Network 
(DAWN). This report describes the results of that review, which 
showed that the estimated number of ED visits for nonmedical 
use of opioid analgesics increased 111% during 2004–2008 
(from 144,600 to 305,900 visits) and increased 29% during 
2007–2008. The highest numbers of ED visits were recorded for 
oxycodone, hydrocodone, and methadone, all of which showed 
statistically significant increases during the 5-year period. The 
estimated number of ED visits involving nonmedical use of ben-
zodiazepines increased 89% during 2004–2008 (from 143,500 
to 271,700 visits) and 24% during 2007–2008. These findings 
indicate substantial, increasing morbidity associated with the 
nonmedical use of prescription drugs in the United States dur-
ing 2004–2008, despite recent efforts to control the problem. 
Stronger measures to reduce the diversion of prescription drugs 
to nonmedical purposes are warranted.
DAWN is a public health information system that tracks the 
impact of drug use, misuse, and abuse in the United States by 
monitoring drug-related hospital ED visits. In a manner similar 
to the National Electronic Injury Surveillance System,* DAWN 
uses a sample of EDs to estimate national ED visit rates (2). 
DAWN collects data from a stratified, simple random sample of 
approximately 220 nonfederal, short-stay, general hospitals that 
operate 24-hour EDs in the United States. DAWN’s sampling 
frame is based on the American Hospital Association annual 
survey database and is updated annually to reflect new, closed, 
merged, and demerged hospitals, and to give new hospitals an 
opportunity to be selected into the sample.
The DAWN sample is designed to produce estimates and 
trends for individual metropolitan areas (12 in 2008) and the 
United States overall (2). To achieve this, the selected metro-
politan areas are oversampled. The oversampled hospitals and a 
supplementary sample of hospitals outside those areas together 
capture ED visits in all 50 states and the District of Columbia. 
Trained DAWN reporters review the medical charts of all 
patients treated in the participating hospital EDs to identify 
visits for conditions induced by or related to drug use. DAWN 
reporters record de-identified information from the ED medi-
cal records using standard abstraction forms. DAWN does not 
conduct interviews or follow-up with clinicians, patients, or 
family members. Rates presented in this report are based on 
the numbers of ED visits weighted so that they are representa-
tive of the U.S. population. Denominators for this report were 
based on U.S. Census postcensal estimates. Differences between 
counts and between rates were tested using two-sided t tests.†
DAWN defines nonmedical use of a prescription or over-
the-counter drug as taking a higher-than-recommended dose, 
taking a drug prescribed for another person, drug-facilitated 
assault, or documented misuse or abuse, all of which must be 
documented in the medical record. DAWN classifies suicide 
attempts, patients seeking detoxification, and unintentional 
ingestions in other categories.
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For 2008, a total of 231 hospitals submitted data 
that were used for estimation. The overall weighted hos-
pital response rate was 32.9% (response rates have been 
stable from year to year). In 2008, DAWN recorded 
351,697 drug-related ED visits. On average, a DAWN 
member hospital submitted 1,522 DAWN cases.
DAWN estimated 1.6 million ED visits for the 
misuse and abuse of all drugs in 2004 and 2.0 million 
in 2008. Among these, illicit drugs such as cocaine and 
heroin were involved in 1.0 million visits in both 2004 
and 2008, whereas prescription or over-the-counter 
drugs used nonmedically were involved in 0.5 mil-
lion visits in 2004 and 1.0 million visits in 2008. The 
estimated number of ED visits involving nonmedical 
use of opioid analgesics§ increased from 144,600 in 
2004 to 305,900 in 2008 (111%, p<0.001), whereas 
rates increased from 49.4 per 100,000 to 100.6 per 
100,000, an increase of 104% (p<0.05).
ED visit rates for opioid analgesics were highest 
for oxycodone, hydrocodone, and methadone during 
the entire study period (Figure 1). Estimated ED 
visits involving oxycodone increased from 41,700 to 
105,200 (p<0.001), and rates increased from 14.2 per 
100,000 to 34.6 per 100,000, an increase of 144% 
(p<0.05). The estimated number of ED visits involv-
ing nonmedical use of benzodiazepines increased from 
143,500 in 2004 to 271,700 in 2008 (89%, p=0.01), 
and rates increased from 49.0 to 89.4 per 100,000, 
an increase of 82% (p<0.05). The increases in num-
bers of ED visits during 2004–2008 for individual 
benzodiazepines were significant: alprazolam (125%, 
p=0.01), clonazepam (72%, p<0.001), diazepam 
(70%, p=0.02), and lorazepam (107%, p=0.006), as 
was the increase for the sleep aid zolpidem (121%, 
† To minimize the effect of nonresponse, the DAWN weighting 
plan includes nonresponse adjustment factors for within-hospital 
nonresponse and hospital nonresponse; the weighting plan also 
includes a poststratification adjustment factor that reconciles the 
weighted number of total visits for responding hospitals with the 
number of total visits from the most recent American Hospital 
Association Annual Survey Database. Estimates for all DAWN-
eligible hospitals in the United States are produced by applying 
poststratified weights to the data received from the sampled 
hospitals. Estimates (and their associated rates and confidence 
intervals) are suppressed if based on an unweighted count of fewer 
than 30 cases, if the estimate is less than 30, or if the relative 
standard error is greater than 50%. The DAWN data collection 
protocol aims for 100% chart review but accepts any percentage 
above 90% as complete. In EDs where chart subsampling has been 
implemented, reporters review 100% of the charts for sampled 
days. Chart subsampling is employed at large facilities with more 
than 3,500 visits per month. In these facilities, charts are typically 
reviewed every other day. Additional information about DAWN is 
available in appendix C at http://dawninfo.samhsa.gov/files/ed2007/
dawn2k7ed.pdf.
§ An additional 60,900 visits involving “opiates/opioids unspecified” 
were not included because some might have involved heroin.
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p=0.002). Carisoprodol-related visits also increased 
significantly (132%, p=0.04). The estimated number 
of visits for alprazolam in 2008 (104,800) was more 
than twice the number for the next most common 
benzodiazepine, clonazepam (48,400).
Although women had more benzodiazepine-
related visits than men (Table), this difference was 
not statistically significant. Among opioid analgesic–
related visits, 38% did not involve any other drug 
(including alcohol); the corresponding figure was 21% 
for benzodiazepine-related visits. Benzodiazepines 
were involved in 26% of opioid analgesic–related 
visits. Alcohol was involved in 15% and 25% of 
visits for opioids and benzodiazepines, respectively. 
Approximately one in four patients was admitted. For 
the year 2008, rates for both types of drugs increased 
sharply after age 17 years, peaked in the 21–24 years 
age group, and declined after age 54 years (Figure 2). 
The largest increases during 2004–2008 occurred 
among persons aged 21–29 years.
Reported by
R Cai, MS, E Crane, PhD, K Poneleit, MPH, Office of 
Applied Studies, Substance Abuse and Mental Health 
Services Admin. L Paulozzi, MD, Div of Unintentional 
Injury Prevention, National Center for Injury Prevention 
and Control, CDC.
TABLE. Estimated number and rate of emergency department visits for nonmedical use of opioid analgesics and benzo-
diazepines, by selected characteristics — United States, 2008
Characteristic
Opioid analgesics Benzodiazepines
No. Rate* 95% CI† No. Rate 95% CI
Total 305,900 100.6 (75.6–125.6) 271,700 89.4 (61.6–117.1)
Sex
Male 150,800 100.6 (74.9–126.3) 119,600 79.7 (57.1–102.4)
Female 155,000 100.6 (75.1–126.1) 152,100 98.7 (64.8–132.5)
No. of drugs (including alcohol)
One drug 116,800 38.4 (31.4–45.4) 56,900 18.7 (15.1–22.3)
Multidrug 189,000 62.2 (42.8–81.6) 214,800 70.6 (45.9–95.4)
Alcohol involvement 46,200 15.2 (10.9–19.5) 68,600 22.6 (14.6–30.6)
Admitted to hospital 72,700 23.9 (15.7–32.1) 81,300 26.8 (14.5–39.0)
Source: Substance Abuse and Mental Health Services Administration (SAMHSA)’s Drug Abuse Warning Network (DAWN), 2004–2008. Additional 
information available in appendix C at http://dawninfo.samhsa.gov/files/ed2007/dawn2k7ed.pdf.
* Per 100,000 population
† Confidence interval.
Source: Substance Abuse and Mental Health Services Administration (SAMHSA)’s Drug 
Abuse Warning Network (DAWN), 2004–2008. Additional information available in appendix C 
at http://dawninfo.samhsa.gov/files/ed2007/dawn2k7ed.pdf.
* Per 100,000 population.
† 95% confidence interval.
§ Rate significantly less than the rate in 2008, by two-sided t test (p<0.05).
¶ Drug types include combination products  (e.g., combinations  of oxycodone and aspirin).
FIGURE 1. Rates of emergency department (ED) visits* for nonmedical use of 






























What is already known on this topic?
Deaths involving the nonmedical use of prescription 
drugs increased in the United States through 2006.
What is added by this report?
Emergency department visits involving nonmedical 
use of two types of prescription drugs, opioid analge-
sics and benzodiazepines, more than doubled during 
2004–2008 in the United States; visits for misused 
prescription and over-the-counter drugs are now as 
common as emergency department visits for use of 
illicit drugs.
What are the implications for public health practice?
Recent public health and law enforcement measures 
intended to prevent nonmedical use of such drugs 
have not prevented rate increases, and additional 
measures are needed urgently.
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Editorial Note
The number of ED visits involving nonmedical use 
of prescription or over-the-counter drugs increased 
rapidly during 2004–2008, and by 2008 matched 
the number of ED visits involving illicit drugs. ED 
visits involving such pharmaceuticals accounted for 
all of the growth in overall drug misuse/abuse rates 
during 2004–2008. ED visits involving opioids or 
benzodiazepines were the largest contributors to the 
increase in ED visits involving the nonmedical use of 
prescription or over-the-counter drugs.
Notably, results from 2008 indicate that in addi-
tion to the large increase in visits compared with 2004, 
peak visit rates for both opioids and benzodiazepines 
appear to have shifted into the 21–24 and 25–29 years 
age groups and away from the 30–34 and 35–44 years 
age groups. As late as 2006, the peak mortality rate 
for fatal drug overdoses involving opioid analgesics 
had been in the 35–54 years age group (1).
The 5-year increase in ED visit rates reflects, in 
part, substantial increases in the prescribing of these 
classes of drugs (3). The increase also might reflect an 
increase in the rate of nonmedical use of prescription 
drugs per 1,000 prescriptions, as has been observed 
for selected opioids (4). In the 2008 National Survey 
of Drug Use and Health (NSDUH), 4.6% of persons 
aged ≥18 years reported past-year nonmedical use of 
prescription pain relievers, and 2.1% reported non-
medical use of tranquilizers, a category that includes 
benzodiazepines (5).
In contrast to the results of this study, NSDUH 
results have shown no increase in self-reported rates 
of nonmedical use of selected pharmaceuticals since 
2004 (5). Increasing ED visit rates in the context 
of stable self-reported nonmedical use rates might 
indicate that persons seen in EDs are different from 
typical respondents to NSDUH; a shift toward riskier 
types of pain relievers and benzodiazepines, riskier 
modes of use, more frequent or heavier use; and/or 
an increased tendency to seek emergency care because 
of greater awareness of the serious consequences of 
nonmedical use of such drugs. However, changes in 
health-seeking behavior would not affect changes in 
drug-related deaths, and DAWN ED visit trends are 
consistent with medical examiner data from six states 
also tracked by DAWN (Maine, Maryland, New 
Hampshire, New Mexico, Utah, and Vermont). In 
these states, the number of nonsuicidal deaths related 
to benzodiazepines increased 64.2%, and the number 
related to opioid analgesics other than methadone 
increased 47.4% during 2004–2007 (6).
The relative magnitudes of the rates shown gen-
erally reflect prescription volumes. For example, the 
benzodiazepine with the highest number of ED visits, 
alprazolam, was the most prescribed benzodiazepine 
in the United States in 2008, with an estimated 44 
million prescriptions (7). However, some exceptions 
exist: hydrocodone was prescribed nearly 124 mil-
lion times and oxycodone nearly 45 million times 
in 2008, but hydrocodone ED rates were not higher 
than oxycodone ED rates. The high frequency of mul-
tidrug involvement is a reflection of the tendency of 
persons who abuse drugs to combine them to moder-
ate or enhance their effects. The lower proportion of 
single-drug ED visits among benzodiazepine ED visits 
compared with opioid analgesic visits is consistent 
with the relative rarity of a benzodiazepine being the 
sole drug involved in a fatal overdose (6,8).
The findings in this report are subject to at least 
four limitations. First, the drugs involved in ED 
visits might not all be identified and documented. 
The extent to which ED staff members document 
drug involvement might have increased over time. 
Second, information on the motivation for use 
might be incomplete; some of the ED visits might 
have represented suicide attempts. Third, rates based 
on population cannot be used to determine risk per 
patient or per prescription. Finally, distinguishing 
drugs taken for nonmedical and medical reasons is 
FIGURE 2. Age-specific rates of emergency department visits* for nonmedical 
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Source: Substance Abuse and Mental Health Services Administration (SAMHSA)’s Drug 
Abuse Warning Network (DAWN), 2004–2008. Additional information available in appendix C 
at http://dawninfo.samhsa.gov/files/ed2007/dawn2k7ed.pdf.
* Per 100,000 population.
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not always possible, especially when multiple drugs 
are involved.
These increases in nonmedical use of pharmaceu-
ticals suggest that previous prevention measures, such 
as provider and patient education and restrictions on 
use of specific formulations, have not been adequate. 
Given the societal burden of the problem, additional 
interventions are urgently needed, such as more sys-
tematic provider education, universal use of state pre-
scription drug monitoring programs by providers, the 
routine monitoring of insurance claims information 
for signs of inappropriate use, and efforts by provid-
ers and insurers to intervene when patients use drugs 
inappropriately (9,10). This report also reinforces the 
value of timely, population-based national surveillance 
for nonmedical use of drugs, which can be used to 
assess the effect of such interventions.
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Prenatal care visits present an opportunity for 
health-care providers to offer services recommended 
by professional societies and educate women regard-
ing behaviors and exposures that might affect their 
pregnancies. To determine whether women who 
identified a need for a service during pregnancy 
received that service, CDC analyzed 2004–2007 
data (the most recent available) from the Pregnancy 
Risk Assessment Monitoring System (PRAMS) for 
Oklahoma and South Carolina, the only two states 
to include questions on the topic on their PRAMS 
questionnaires. This report summarizes the results of 
that analysis, which indicated substantial differences 
between perceived need and receipt of 1) assistance 
in reducing violence in the home, 2) counseling 
information for family or personal problems, 3) help 
to quit smoking, 4) help with an alcohol or drug 
problem, and 5) dental care. In South Carolina and 
Oklahoma, respectively, 1.7% and 2.9% of pregnant 
women stated a need for help to reduce violence 
in the home. Of those, only 12.8% and 21.0% 
reported receiving that help. In South Carolina and 
Oklahoma, respectively, 7.4% and 12.6% of pregnant 
women stated a need for help to quit smoking during 
pregnancy; of those, only 29.1% and 30.4% reported 
receiving that help. Adherence by health-care pro-
viders to established guidance for treating pregnant 
women might help reduce the differences between 
perceived need and receipt of services. Additional 
research to identify obstacles to receipt of services 
might enable state programs to further narrow these 
differences.
PRAMS is a population-based surveillance sys-
tem that collects data on a wide range of maternal 
behaviors and experiences before, during, and after 
pregnancy. PRAMS surveys currently are conducted 
in 37 states and New York City. Each month, par-
ticipating sites select a stratified random sample of 
100–300 women with recent live births from birth 
certificate records. A questionnaire is mailed to the 
women 2–6 months after delivery. The participating 
sites use a standard core PRAMS questionnaire, to 
which they can add questions. Women receive up 
to three questionnaire mailings, and nonresponders 
receive follow-up telephone calls.
CDC analyzed PRAMS data collected from 7,824 
respondents in Oklahoma and 5,474 respondents in 
South Carolina during 2004–2007; survey response 
rates ranged from 71% to 80% for Oklahoma and 
from 68% to 72% for South Carolina. For South 
Carolina, the 2006 data represented births only from 
April through September.
Oklahoma and South Carolina are the only 
two states to add PRAMS questions regarding the 
self-identified need for selected health services dur-
ing pregnancy and the subsequent receipt of those 
services. Regarding needed services, all participants 
were asked, “During your most recent pregnancy, did 
you feel you needed any of the following services?” 
Five services with response choices of “yes” or “no” 
were listed in both state’s surveys: help to reduce 
violence in your home, counseling information for 
family or personal problems, help to quit smoking, 
help with an alcohol or drug problem, and help with 
or information about breastfeeding. Two additional 
services were listed in the Oklahoma survey only: 
dental care and nutrition services (i.e., food stamps; 
Women, Infants, and Children program; or money 
to buy food). Two additional services also were listed 
in the South Carolina survey only: parenting classes 
and childbirth classes. Regarding receipt of services, 
all participants also were asked, “During your most 
recent pregnancy, did you receive any of the following 
services?” The same services were listed.
Data were weighted in each state to account for 
complex survey design, nonresponse, and noncov-
erage. The statistical significance of differences was 
determined using a chi-square test, with significance 
determined at p<0.05.
Characteristics of survey participants in Oklahoma 
and South Carolina during 2004–2007 relating to 
total number of live births and Medicaid payment 
for prenatal-care were similar (Table 1). However, 
the weighted percentages of the participant groups 
by race/ethnicity, age, education level, marital status, 
and prenatal care initiation differed significantly. For 
Perceived Health Needs and Receipt of Services During Pregnancy — 
Oklahoma and South Carolina, 2004–2007
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example, in Oklahoma, 67.3% of participants were 
non-Hispanic white, 8.3% were non-Hispanic black, 
12.8% were Hispanic, and 11.7% were of other races. 
In contrast, in South Carolina, 56.7% of participants 
were non-Hispanic white, 31.8% were non-Hispanic 
black, 8.8% were Hispanic, and 2.6% were of other 
races (Table 1).
In Oklahoma, the needs most commonly reported 
were for dental care (50.1%), nutrition assistance 
(48.0%), and help with or information about 
breastfeeding (30.0%) (Figure). In South Carolina, 
the needs most commonly reported were for help 
with or information about breastfeeding (35.3%), 
childbirth classes (27.6%), and parenting classes 
(17.7%) (Figure).
In both states, substantial differences were 
observed between the percentages of women who 
perceived needs for services and the percentages of 
that group who received those services. In Oklahoma 
and South Carolina, the widest differences were 
regarding help to reduce violence in the home. Of the 
2.9% of women in Oklahoma and 1.7% of women 
in South Carolina who identified that need during 
pregnancy, 21.0% and 12.8% reported receiving 
the service, respectively. Among women who said 
they needed services in Oklahoma, 27.4% reported 
receiving counseling information for family or per-
sonal problems; 30.4% received help to quit smok-
ing; 34.8% received help with an alcohol or drug 
problem; and 38.2% received dental care (Table 2). 
In South Carolina, after help to reduce violence in 
the home, the widest differences were for help to quit 
smoking (29.1%) and getting counseling informa-
tion for family or personal problems (30.0%) (Table 
2). Among services included in the surveys of both 
states, the narrowest difference was observed regard-
ing help with information about breastfeeding. In 
Oklahoma, 82.4%, and in South Carolina, 79.8%, 
of those who perceived a need for breastfeeding help 
received the service.
Reported by
S Dooley, MS, A Lincoln, MSW, MSPH, Oklahoma 
State Dept of Health. M Smith, MSPH, South Caro-
lina Dept of Health and Environmental Control. ME 
O’Neil, MPH, IB Ahluwalia, PhD, DV D’Angelo, 
MPH, B Morrow, MA, Div of Reproductive Health, 
National Center for Chronic Disease Prevention and 
Health Promotion, CDC.
Editorial Note
The findings in this report identify differences 
between the perceived needs and receipt of certain 
health services to fill those needs by pregnant women 
in Oklahoma and South Carolina, despite established 
guidance for providers to offer these supportive 
services. For example, only 30.4% of women in 
Oklahoma who perceived a need during pregnancy 
for help to quit smoking, and 29.1% of women in 
South Carolina, received that help. Nationally, an 
estimated 14% of women smoke during pregnancy, 
a behavior associated with intrauterine growth 
restriction, spontaneous abortion, low birth weight, 
and preterm delivery (1). The American College of 
TABLE 1. Characteristics of women with recent live births — Pregnancy Risk Assess-






%† (95% CI§) %† (95% CI)
Race/Ethnicity¶
White, non-Hispanic 67.3 (65.6–69.1) 56.7 (54.5–58.9)
Black, non-Hispanic 8.3 (7.3–9.3) 31.8 (29.8–33.9)
Hispanic 12.8 (11.5–14.1) 8.8 (7.6–10.2)
Other 11.7 (10.5–12.9) 2.6 (2.0–3.4)
Age group (yrs)¶
 ≤17 3.7 (3.1–4.6) 4.4 (3.6–5.4)
 18–24 40.6 (38.8–42.5) 38.1 (35.9–40.2)
 25–29 30.4 (28.7–32.1) 26.4 (24.6–28.4)
 ≥30 25.3 (23.8–26.8) 31.1 (29.2–33.1)
Education level¶
<12th grade 20.3 (18.8–22.0) 23.4 (21.5–25.4)
12th grade 38.0 (36.2–39.8) 25.6 (23.7–27.6)
>12th grade 41.6 (39.9–43.4) 51.1 (48.9–53.2)
Marital status¶
Married 60.1 (58.3–62.0) 57.0 (54.8–59.2)
Not married 39.9 (38.0–41.7) 43.0 (40.8–45.2)
Total no. of live births
 1 40.5 (38.7–42.3) 42.1 (40.0–44.2)
 2 31.5 (29.8–33.2) 32.9 (30.9–35.0)
 ≥3 28.1 (26.5–29.7) 25.0 (23.2–27.0)
Medicaid paid for prenatal care
Yes 51.1 (49.2–52.9) 52.8 (50.5–55.0)
No 48.9 (47.1–50.9) 47.2 (45.0–49.5)
Prenatal care initiation¶
In first trimester 79.8 (78.3–81.3) 76.8 (74.8–78.7)
After first trimester 18.6 (17.2–20.1) 22.3 (20.5–24.3)
No prenatal care 1.5 (1.1–2.1) 0.8 (0.5–1.4)
* Unweighted number of participants.
† Weighted percentage.
§ Confidence interval.
¶ Significant differences between the two states (p<0.05, chi-square test).
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Obstetricians and Gynecologists (ACOG) recom-
mends that physicians screen and counsel pregnant 
women regarding smoking cessation; ACOG has 
found that 46% of women who smoked before 
pregnancy quit during pregnancy (2).
The findings show that only 34.8% of women in 
Oklahoma and 35.8% of women in South Carolina 
who perceived a need for help with an alcohol or 
drug problem received that help. A joint statement 
by ACOG and the American Academy of Pediatrics 
advises physicians to screen for alcohol use during 
pregnancy because prenatal exposure to alcohol is a 
leading preventable cause of fetal neurodevelopmen-
tal disorders (3). ACOG also recommends screening 
for illicit drug use and provides physicians with tools 
to identify and treat drug abuse (3).
The data also show that only 21.0% and 12.8% 
of postpartum women in Oklahoma and South 
Carolina, respectively, who felt a need for help dur-
ing pregnancy in reducing violence in their home 
received that help. The prevalence of women in 
Oklahoma and South Carolina reporting intimate 
partner violence during pregnancy was 4.4% and 
2.7%, respectively, in 2007 (4). The American 
College of Nurse-Midwives (ACNM) recommends 
that health-care providers attempt to identify inti-
mate partner violence and provide information on 
resources available to women (5).
The most commonly reported need in Oklahoma 
was dental care, a need perceived by 50.1% of 
 * Help with an alcohol or drug problem, help to reduce violence in the home, help to quit 
smoking, counseling for family or personal problems, help with or information about 
breastfeeding, nutrition services, dental care, parenting classes, and childbirth classes.
 † Unweighted number of participants.
 § Women who felt a need and also received the service.
 ¶ Weighted percentage.
 ** 95% confidence interval.
 †† Oklahoma survey only.
 §§ South Carolina survey only.
FIGURE. Percentage of women with recent live births who felt a need for 
selected health services during pregnancy, by type of service* and receipt 
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What is already known on this topic?
Established guidance is available for health-care 
providers regarding key services for pregnant and 
postpartum women.
What is added by this report?
In Oklahoma and South Carolina, substantial differ-
ences were identified between the perceived needs of 
pregnant women for certain key services and receipt 
of those services.
What are the implications for public health practice?
Adherence by health-care providers to established 
guidance for treating pregnant women might help 
reduce the differences between perceived need and 
receipt of services; additional research at the state 
level might identify reasons why more pregnant 
women do not receive services after identifying needs.
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23 713 
women who delivered live-born infants and not to 
all women who were pregnant. Second, contextual 
information regarding the services was not collected, 
such as information that might indicate the degree 
to which women sought the needed services or why 
they were not able to obtain them (e.g., lack of 
dental care coverage). Finally, all PRAMS data are 
self-reported and subject to recall bias if women did 
not accurately remember what needs they had and 
services they received during pregnancy.
The PRAMS surveillance system was established 
to provide state-level data on women’s health before, 
during, and after pregnancy to help health agencies 
and researchers monitor trends in maternal and 
infant health indicators. Other states might consider 
collecting information on women’s perceived need 
and receipt of services during pregnancy. Continued 
use of PRAMS data to monitor access to services 
is important for evaluating and setting priorities 
for future initiatives to address issues important to 
women and their families.
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pregnant women, but a service received by only 
38.2% of those who cited the need. The American 
Academy of Periodontology recommends women 
visit dentists for care during their pregnancy (6). 
However, a survey of obstetrician-gynecologists 
found that 38% did not advise their patients to seek 
dental care, and 77% reported their patients had 
declined dental services because they were pregnant, 
despite evidence showing that receipt of oral health 
care during pregnancy is safe (7).
An encouraging finding is that, in both Oklahoma 
and South Carolina, approximately 80% of women 
who perceived a need for breastfeeding support 
received it. ACOG and ACNM recommend that 
health-care professionals, hospitals, and employ-
ers support women who choose to breastfeed their 
infants (8,9). Breastfeeding initiation rates increased 
nationally from 26.5% in the 1970s to 74.2% in 
2005 (10). This gain can, in part, be attributed to 
an increased number of health-care providers edu-
cating women on breastfeeding, lactation support, 
breastfeeding accommodations in the workplace, 
and legislation that has created a more supportive 
environment for breastfeeding women (10).
The findings in this report are subject to at least 
three limitations. First, the results apply only to 
TABLE 2. Percentage of women with recent live births who felt a need for selected health services during pregnancy and who received those 





Felt  need 
Received 
service
% of those who 
felt need who 
subsequently 
received 
service Felt need 
Received 
service
% of those who 




Type of service No.*  %† (95% CI§)  %¶ (95% CI)  % (95% CI) No.  % (95% CI)  % (95% CI)  % (95% CI)
Help to reduce violence in the home 240  2.9 (2.3–3.6)  0.6 (0.4–1.0)  21.0 (13.2–31.8) 115  1.7 (1.2–2.4)  0.2 (0.1–0.5)  12.8 (5.9–25.7)
Counseling information for family 
or personal problems
1,229  15.9 (14.6–17.4)  4.4 (3.7–5.2)  27.4 (23.4–31.8) 538  8.9 (7.7–10.3)  2.7 (2.0–3.5)  30.0 (23.6–37.2)
Help to quit smoking 1,032  12.6 (11.4–13.9)  3.8 (3.1–4.6)  30.4 (25.6–35.6) 415  7.4 (6.3–8.6)  2.1 (1.6–2.9)  29.1 (22.1–37.3)
Help with an alcohol or drug problem 104  1.6 (1.2–2.2)  0.6 (0.3–1.0)  34.8 (21.5–50.9) 66  0.8 (0.5–1.3)  0.3 (0.1–0.6)  35.8 (16.8–60.7)
Dental care** 3,753  50.1 (48.2–51.9)  19.1 (17.7–20.6)  38.2 (35.7–40.8) —  — —  — —  — —
Parenting classes†† —  — —  — —  — — 1,011  17.7 (16.0–19.4)  10.0 (8.8–11.4)  56.7 (51.5–61.8)
Childbirth classes†† —  — —  — —  — — 1,507  27.6 (25.7–29.6)  18.3 (16.7–20.0)  66.4 (62.4–70.3)
Help with or information about 
breastfeeding
2,472  30.0 (28.3–31.7)  24.7 (23.2–26.3)  82.4 (79.7–84.8) 2,039  35.3 (33.2–37.4)  28.2 (26.3–30.2)  79.8 (76.8–82.6)
Food stamps; Women, Infants, and Children 
program; or money to buy food**
3,543  48.0 (46.2–49.9)  42.5 (40.7–44.4)  88.6 (86.8–90.2) —  — —  — —  — —
 * Unweighted number of participants.
 † Weighted percentages.
 § Confidence interval.
 ¶ Women who felt a need and also received a service.
** Oklahoma survey only.
 †† South Carolina survey only. 
MMWR  Morbidity and Mortality Weekly Report
714 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23
References
 1. CDC. Trends in smoking before, during, and after 
pregnancy—Pregnancy Risk Assessment Monitoring System 
(PRAMS), United States, 31 sites, 2000–2005. Surveillance 
Summaries. May 29, 2009. MMWR 2009;58(No. SS-4).
 2. American College of Obstetricians and Gynecologists. ACOG 
committee opinion no. 316: smoking cessation during 
pregnancy. Obstet Gynecol 2005;106:883–8.
 3. American College of Obstetricians and Gynecologists. ACOG 
committee opinion no. 422: at-risk drinking and illicit drug 
use: ethical issues in obstetric and gynecologic practice. Obstet 
Gynecol 2008;112:1449–60.
 4. CDC. CPONDER—CDC’s PRAMS on-line data for epidem-
iologic research. Available at http://www.cdc.gov/prams/ 
cponder.htm. Accessed November 18, 2009.
 5. American College of Nurse-Midwives. Position statement: 
violence against women. Silver Spring, MD: American 
College of Nurse-Midwives; 2003. Available at http://www.
midwife.org/sitefiles/position/violence_against_women_05.
pdf. Accessed June 11, 2010.
 6. American Academy of Periodontology. American Academy of 
Periodontology statement regarding periodontal management 
of the pregnant patient. J Periodontol 2004;75:495.
 7. Morgan MA, Crall J, Goldenberg RL, Schulkin J. Oral 
health during pregnancy. J Matern Fetal Neonatal Med 
2009;22:733–9.
 8. American College of Obstetricians and Gynecologists. ACOG 
committee opinion no. 361: breastfeeding: maternal and 
infant aspects. Obstet Gynecol 2007;109(2 Pt 1):479–80.
 9. American College of Nurse-Midwives. Position statement: 
breastfeeding. Silver Spring, MD: American College of 
Nurse-Midwives; 2003. Available at http://www.midwife.
org/sitefiles/position/breastfeeding_05.pdf. Accessed June 
11, 2010.
 10. Grummer-Strawn LM, Shealy KR. Progress in protecting, 
promoting, and supporting breastfeeding: 1984–2009. 
Breastfeed Med 2009;4(Suppl 1):S31–9.
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23 715 
or CDC are classified as travel-associated unless they 
are identified specifically as locally acquired.
Cases submitted to ArboNET are classified as 
probable or laboratory-confirmed by the reporting 
jurisdiction; specimens submitted to CDC are clas-
sified as probable or laboratory-confirmed based 
on testing conducted at CDCDB. Probable cases 
are defined by a single immunoglobulin M (IgM) 
specimen in late acute phase or convalescent phase of 
illness. Laboratory-confirmed cases are defined by a 
positive polymerase chain reaction (PCR) test result 
or by viral isolation.
During 2006–2008, 57 duplicate reports were 
reported to both ArboNET and CDCDB and were 
assigned to CDCDB. During that period, ArboNET 
received reports of 596 cases, of which 468 (79%) 
were reported as probable and 128 (21%) were 
reported as laboratory-confirmed.
During 2006–2008, CDCDB received a total of 
529 specimens from 524 patients in 41 states and 
DC for dengue testing (153 in 2006, 272 in 2007, 
and 104 in 2008). Of the 529 specimens, 136 (26%) 
resulted in a diagnosis of dengue. Among those 136 
specimens, 106 (78%) had elevated antidengue IgM 
antibodies (probable recent dengue infection), and 
30 (22%) had a dengue virus identified in serum by 
either reverse transcription–polymerase chain reaction 
(RT-PCR) or viral isolation (confirmed acute dengue 
infection). Serotype specific data were available for 
those 30 cases, of which 14 were DENV-1, seven 
were DENV-2, six were DENV-3, and three were 
DENV-4. Results for 162 (31%) specimens were 
classified as indeterminate because blood samples were 
not collected within specified timeframes. Among the 
215 patients (41% of all specimens received) whose 
laboratory results were negative (RT-PCR or IgM 
negative, or no virus isolated), 38 (18%) had evidence 
of past flavivirus infection. In addition, the amount 
of serum provided for 16 (3%) of the patients was 
insufficient for testing, and in one sample the infect-
ing virus could not be identified.
The 596 case reports were received by ArboNET 
from 25 states; more than half (57%) were reported 
from three states: 178 (30%) from New York, 99 
(17%) from Florida, and 61 (10%) from Texas. 
Among the 136 dengue-positive cases identified by 
CDCDB, 42 (31%) were submitted from New York, 
Dengue is caused by four antigenically related 
viruses (DENV-1, DENV-2, DENV-3, and DENV-
4). Dengue fever is endemic in most tropical and 
subtropical areas of the world, and in 2007 nearly 1 
million cases were reported in the Americas alone. 
Dengue infections commonly occur among U.S. 
residents returning from travel to endemic areas (1–4) 
and are more prevalent than malaria among return-
ing travelers from the Caribbean, South America, 
South Central Asia, and Southeast Asia (5). This 
report summarizes information about dengue cases 
reported to CDC through two CDC-maintained 
passive surveillance systems: 1) the ArboNET surveil-
lance system, a national CDC arboviral surveillance 
system maintained by CDC’s Arboviral Diseases 
Branch and initially developed in response to the 
introduction of West Nile virus in the United States, 
and 2) a system maintained for decades by the CDC 
Dengue Branch (CDCDB), which collects informa-
tion on all suspected dengue cases whose specimens 
are sent to the branch. During 2006–2008, a total of 
1,125 unique reports were made to either ArboNET 
or CDCDB. Of these, the highest proportion of 
laboratory-confirmed and probable cases with known 
travel histories were in persons who reported travel 
to the Dominican Republic (121; 20%), Mexico 
(55; 9%), and India (43; 7%). Health-care providers 
should consider dengue in the differential diagnosis 
of patients with a history of travel to endemic areas 
within 14 days of fever onset.
Dengue cases are reported to ArboNET from state 
and metropolitan health departments. The dengue 
surveillance system at CDCDB receives reports of 
suspected dengue cases among U.S. travelers from 
clinicians and officials at state health departments, 
who forward patient specimens to CDC for diagnostic 
testing. Age, sex, birth date, and onset date are used to 
match cases reported to both systems, and duplicate 
cases are eliminated.
For both CDCDB and ArboNET, a case of 
laboratory-diagnosed infection (i.e., probable or 
laboratory-confirmed) in a resident of one of the 50 
states or the District of Columbia (DC) who traveled 
in the 14 days before symptom onset to a dengue-
endemic area outside the 50 states. Because autochtho-
nous dengue transmission in the continental United 
States is uncommon, all cases reported to ArboNET 
Travel-Associated Dengue Surveillance — United States, 2006–2008
MMWR  Morbidity and Mortality Weekly Report
716 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23
among whom country-specific travel information 
was available for 613 (95%). By region, 262 persons 
(43%) had traveled to the Caribbean; 208 (34%) to 
Mexico, Central America, or South America; 131 
(21%) to Asia and the Pacific; and 12 (2%) to Africa. 
By country, 121 persons (20%) reported travel to the 
Dominican Republic, 55 (9%) to Mexico, and 43 
(7%) to India during the 14 days before illness onset 
(Table 1). One laboratory-confirmed case reported to 
ArboNET from Texas in 2008 was characterized as 
17 (13%) from Massachusetts, 10 (7%) from Arizona, 
and 10 (7%) from Georgia. Males accounted for 52% 
of all cases reported to ArboNET and 54% of posi-
tive specimens to CDCDB. Median age of patients 
was similar for both systems; 40 years and 42 years, 
respectively.
Of the 732 confirmed and probable cases from 
ArboNET and CDCDB combined (596 cases from 
ArboNET and 136 positive cases from CDC), his-
tory of travel was reported by 649 persons (89%), 
TABLE 1. Cases* of imported dengue reported to ArboNET and CDC Dengue Branch (CDCDB), by state, 2006–2008†
Reported to CDCDB Reported to ArboNET Total 





of laboratory-confirmed dengue 
(No. of laboratory-positive 









Alabama 0 0 6 2 Brazil, Indonesia 6 2
Alaska 1 0 0 0 1 0
Arizona 9 1 Dominican Republic (DENV-1) 13 0 22 1
Arkansas 0 0 0 0 0 0
California 2 0 0 0 2 0
Colorado 1 2 Costa Rica (DENV-1), St. Barthelemy 
(DENV-2)
0 0 1 2
Connecticut 1 1 Unknown (DENV-1) 0 0 1 1
Delaware 0 0 0 2 India, Tahiti 0 2
District of Columbia 0 0 0 0 0 0
Florida 0 1 St. Lucia (DENV-2) 89 10 Brazil, Costa Rica, Dominican Republic (2), 
El Salvador, Guatemala and Honduras, 
Mexico, Puerto Rico (3)
89 11
Georgia 6 4 Costa Rica (DENV-1), Honduras (2, DENV-1), 
India (DENV-3)
0 12 Dominican Republic, Haiti, Honduras (2), 
India (2), Mexico, Nicaragua, Nigeria, 
Puerto Rico, St. Barthelemy (2)
6 16
Hawaii 6 2 Unknown (DENV-1), unknown (DENV-2) 0 0 6 2
Idaho 0 0 0 0 0 0
Illinois 1 0 6 0 7 0
Indiana 0 0 0 0 0 0
Iowa 0 0 12 0 12 0
Kansas 0 0 0 0 0 0
Kentucky 0 0 0 0 0 0
Louisiana 1 0 0 0 1 0
Maine 7 1 Haiti, Turks, and Caicos (DENV-1) 2 0 9 1
Maryland 0 2 Tahiti (2, DENV-1) 0 0 0 2
Massachusetts 13 4 Costa Rica (DENV-1), New Zealand 
(DENV-1), Puerto Rico (DENV-3), 
St. Kitt’s (DENV-3).
0 0 13 4
Michigan 1 0 0 0 1 0
Minnesota 0 0 44 0 44 0
Mississippi 0 0 0 0 0 0
Missouri 2 0 10 0 12 0
Montana 0 0 0 0 0 0
Nebraska 0 0 0 0 0 0
Nevada 1 0 6 1 Dominican Republic 7 1
New Hampshire 0 0 2 2 Brazil, India 2 2
New Jersey 0 2 Puerto Rico (2, DENV-2) 0 0 0 2
New Mexico 0 0 2 0 2 0
New York 38 4 Dominican Republic (2),  (DENV-1, 
DENV-4), Haiti (DENV-1), St. Martin 
and Antilles (DENV-3)
158 20 Bangladesh (2), Caribbean (unspecified), 
Dominican Republic (3), Guatemala (4), 
Haiti and Zambia, India, Indonesia (2), 
Mexico, Peru, Puerto Rico (2), unknown (2)
196 24
North Carolina 5 0 4 0 9 0
North Dakota 0 0 0 0 0 0
Ohio 1 2 India (DENV-2), Cambodia (DENV-3) 22 0 23 2
Oklahoma 0 0 3 2 Mexico, St. Barthelemy 3 2
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“not imported,” with no travel history, and might have 
represented autochthonous dengue transmission.
For ArboNET cases, the type of clinical syndrome 
was recorded in 596 cases; 429 (72%) were categorized 
as uncomplicated fever, 95 (16%) as dengue hemor-
rhagic fever or dengue shock syndrome, 56 (9%) as 
other syndrome or unknown, and 16 (3%) as den-
gue with hemorrhage (Table 2). For CDCDB cases, 
clinical syndrome was recorded for 54 (40%) of 136 
laboratory-diagnosed cases; 32 (59%) were classified 
as dengue fever, four (7%) cases as dengue hemor-
rhagic fever, and no cases of dengue shock syndrome. 
The most frequently reported signs and symptoms 
included 77 (57%) cases with fever, 57 (42%) with 
headache, and 55 (40%) with body ache. Among 
the 136 CDCDB cases, 27 (20%) included at least 
one hemorrhagic symptom (e.g., petechiae, purpura, 
TABLE 1. (Continued) Cases* of imported dengue reported to ArboNET and CDC Dengue Branch (CDCDB), by state, 2006–2008†
Reported to CDCDB Reported to ArboNET Total 





of laboratory-confirmed dengue 
(No. of laboratory-positive 









Oregon 1 0 0 0 1 0
Pennsylvania 0 1 Unknown (DENV-3) 13 8 Bangladesh, Honduras, Jamaica, 
Puerto Rico (3), St. Martin, Thailand
13 9
Rhode Island 0 0 0 0 0 0
South Carolina 0 0 0 1 Puerto Rico 0 1
South Dakota 1 0 2 1 Haiti 3 1
Tennessee 0 0 0 0 0 0
Texas 6 1 Maldives (DENV-2) 22 39 Bangladesh (2), Brazil (2), El Salvador 
(2), Guatemala, Honduras (2), India (6), 
Malaysia, Mexico (6), Pakistan, Panama, 
Paraguay, Philippines, Puerto Rico (5), 
Singapore (2),Tahiti, Thailand, unknown 
(2), Venezuela (2)
28 40
Utah 0 0 0 0 0 0
Vermont 0 0 0 0 0 0
Virginia 0 1 St. Barthelemy and St. Thomas (DENV-4) 25 5 Costa Rica, El Salvador, Jamaica, Puerto 
Rico, St. Thomas
25 6
Washington 0 0 21 7 El Salvador, Honduras, Nicaragua (3), 
Philippines, Sri Lanka
21 7
West Virginia 0 0 2 0 2 0
Wisconsin 1 0 4 16 Costa Rica (2), Granada, Guatemala 
and Mexico, Honduras, Laos, Mexico 
(3), Nicaragua, Nigeria, Puerto Rico (2), 
St. Lucia, Saudi Arabia, Thailand
5 16
Wyoming 1 1 Ecuador (DENV-4) 0 0 1 1
Total 106 30 468†† 128§§ 574 158
 * Includes probable and laboratory-confirmed cases.
 † CDCDB received a total of 529 specimens. The 596 total cases reported to ArboNET are the sum of probable (468) and confirmed (128) cases.  
 § Probable is defined as a single immunoglobulin M (IgM)-positive specimen in late acute phase or convalescent phase of illness.
 ¶ Laboratory-confirmed results were positive by polymerase chain reaction (PCR) or viral isolation.
 ** If not specified otherwise, the number of cases from each country is one. Unknown indicates that no location-specific travel history was provided. Does not include travel destinations of 
persons with probable cases.
 †† Of the 518 probable cases reported to ArboNET, 50 probable cases also were reported to CDCDB. These 50 probable cases were subtracted from the ArboNET total and included in the 
CDCDB total, resulting in 468 probable cases.
 §§ Of 135 laboratory-confirmed cases reported to ArboNET, seven laboratory-confirmed cases also were reported to CDCDB. These seven cases were subtracted from the ArboNET total and 
included in the CDCDB total, resulting in 128 laboratory-confirmed cases.
What is already known on this topic?
Dengue infections commonly occur among U.S. resi-
dents returning from travel to endemic areas and are 
more prevalent than malaria among returning travel-
ers from the Caribbean, South America, South Central 
Asia, and Southeast Asia.
What is added by this report?
During 2006–2008, an average of 244 confirmed and 
probable travel-associated dengue cases annually 
were identified by two CDC-maintained passive 
surveillance systems, substantially more than the 33.5 
cases (range: 13–77 cases) identified annually during 
1990–2005.
What are the implications for public health practice?
Health-care providers should consider dengue in the 
differential diagnosis of patients with a history of travel 
to endemic areas within 14 days of fever onset.
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hemoptysis, hematemesis, hematuria, vaginal bleed-
ing, bleeding gums, or epistaxis). A higher proportion 
of cases submitted to ArboNET (292; 49%) resulted 
in hospitalization compared with CDCDB cases 
(26; 19%). One travel-associated dengue fatality was 
laboratory confirmed by CDCDB.
Reported by
R Luce, DVM, A Rivera, MS, H Mohammed, PhD, 
KM Tomashek, MD; Dengue Br, J Lehman, Arboviral 
Diseases Br, Div of Vector-Borne Infectious Diseases, 
National Center for Zoonotic, Vector-Borne, and Enteric 
Diseases, CDC.
Editorial Note
During 2006–2008, an average of 244 con-
firmed and probable travel-associated dengue cases 
were identified by ArboNET or CDCDB annually 
(Figure), compared with an annual average of 33.5 
cases (range:13–77 cases) identified during 1990–
2005. Most of this increase likely resulted from the 
2003 addition of dengue reporting to the ArboNET 
surveillance system, which supplements CDCDB 
(6). However, a portion of the increase also likely 
resulted from substantial increases in dengue inci-
dence throughout subtropical and tropical areas of 
the world, including the Americas (6). During 2006–
2008, dengue outbreaks were reported in numerous 
countries, including Belize, Brazil, Costa Rica, Cuba, 
Ecuador, El Salvador, Guadeloupe, India, Madagascar, 
Martinique, Mexico, Nicaragua, Pakistan, Paraguay, 
the United States (Puerto Rico, U.S. Virgin Islands), 
Venezuela, and multiple island nations in the South 
Pacific. Most U.S. residents become infected during 
travel to tropical and subtropical areas outside the 
continental United States, although autochthonous 
transmission has been documented on multiple occa-
sions since 1980 in Texas (7,8), during 2001–2002 in 
Hawaii (9), and during 2009–2010 in Florida (10).
Dengue has an incubation period of 3–14 days. 
Because U.S. travelers spend a median of 10 nights 
abroad, many returning travelers who are infected 
could be viremic and able to infect endemic Aedes 
spp. vector mosquitoes (principally Ae. aegypti and 
Ae. albopictus) in some locations in the continental 
United States, thus creating the potential for localized 
dengue transmission. Clinically recognized cases of 
travel-associated dengue likely underestimate the risk 
for importation because many dengue infections are 
asymptomatic or mildly symptomatic (Box).
TABLE 2. Characteristics of laboratory-confirmed cases of 
dengue among U.S. travelers — combined ArboNET and 










 ≤20 118 (16)
 21–40 256 (35)
 41–60 243 (33)
 >60 95 (13)
Unknown 20 (3)
Clinical syndrome
Dengue fever 32 (4)
Dengue fever with hemorrhage 34 (5)
Dengue hemorrhagic fever/Dengue shock 
syndrome
99 (14)
Other clinical 36 (5)





* Cases were reported via ArboNET or to CDCDB; 57 cases were 
detected in both systems.
† Might not add to 100% because of rounding.
* Based on 1996–2005 data from CDCDB, and 2006–2008 data from the CDCDB and ArboNET 
electronic surveillance system.
† Source: Office of Travel and Tourism Industries. 2007 United States resident travel abroad. 
Washington, DC: US Department of Commerce, International Trade Administration, Office of 
Travel and Tourism Industries; 2008. Available at http://www.tinet.ita.doc.gov/outreachpages/
download_data_table/2007_us_travel_abroad.pdf.
FIGURE. Number and incidence of laboratory-confirmed cases* per 100 million U.S. 








No. of cases (N = 1,093 cases)















MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23 719 
The findings in this report are subject to at least 
three limitations. First, these surveillance results likely 
are subject to underreporting because both CDCDB 
and ArboNET are based on passive reporting (i.e., 
each rely on public health jurisdictions and health-
care providers to detect and report infection) and 
dengue was designated a nationally notifiable disease 
in the United States in 2010, after the ending date 
of this report. Second, cases submitted to ArboNET 
BOX. Dengue surveillance and diagnosis
After the Council of State and Territorial 
Epidemio logists (CSTE) recommended addi-
tion of dengue to the list of nationally notifiable 
diseases, in January 2010, CDC added dengue 
to the list. Public health jurisdictions are encour-
aged to report cases via the ArboNET system. 
Health-care providers are encouraged to submit 
specimens to the CDC Dengue Branch for diag-
nostic testing, as follows:
•	 Obtain	an	acute	phase	(0–5	days	after	onset	of	
symptoms) serum sample, for directly detecting 
dengue virus.
•	 Obtain	 a	 convalescent	 phase	 serum	 sample,	
preferably 1–2 weeks after the first sample, for 
detecting antidengue antibody. Serologic test-
ing can detect diagnostic levels of antidengue 
immunoglobulin M antibody for approxi-
mately 30 days after symptom onset and longer 
in some patients.
•	 To	 obtain	 viral	 identification	 and	 serologic	
diagnosis, send specimens through state or 
territorial health departments to the Dengue 
Branch, Division of Vector-Borne Infectious 
Diseases, National Center for Infectious 
Diseases, 1324 Calle Cañada, San Juan, PR 
00920-3860; telephone 787-706-2399; fax 
787-706-2496.
•	 Attach	a	summary	of	clinical	and	epidemio-
logic information to all serum samples; be sure 
to include date of disease onset, date of sample 
collection, and detailed recent travel history.
Additional information is available at http://www. 
cdc.gov/dengue/resources/testpoleng_2.pdf.
were classified as either probable or laboratory-
confirmed by the reporting jurisdiction largely based 
on interpretation of laboratory results from private 
laboratories using several different laboratory diag-
nostic tests, which might have affected classification 
and reporting of results. Finally, travel histories and 
clinical information were not available for all cases 
and might not have been representative of all persons 
with travel-associated dengue.
Travelers to tropical areas can reduce their risk 
for dengue by avoiding exposure to mosquitoes. No 
vaccine is available for preventing dengue infection. 
Persons traveling to areas where dengue is endemic 
should use insect repellents, wear protective clothing, 
and reside in facilities with screens and air condi-
tioning when available. Preventing travel-associated 
dengue not only benefits the traveler, but also helps 
prevent the introduction of dengue virus into tropi-
cal areas and subtropical areas of the United States 
(primarily the southeastern states), where vector 
mosquitoes could transmit the virus indigenously.
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Errata: Vol. 59, No. SS-2
In the Surveillance Summary, “Surveillance for 
Human West Nile Virus Disease — United States, 
1999–2008,” the values in the legend for Figure 6 on 
page 12 were incorrect. The figure legend should read 
as follows (from darkest to lightest shading): ≥2.00, 
1.50–1.99, 1.00–1.49, 0.50–0.99, 0.01–0.49, and 
0.00.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — — 1 — 1 1 —
Botulism, total — 32 3 116 145 144 165 135
 foodborne — 4 0 10 17 32 20 19
 infant — 21 2 81 109 85 97 85
 other (wound and unspecified) — 7 0 25 19 27 48 31
Brucellosis 1 43 2 115 80 131 121 120 CA (1)
Chancroid — 26 0 28 25 23 33 17
Cholera — 2 0 10 5 7 9 8
Cyclosporiasis§ — 32 12 141 139 93 137 543
Diphtheria — 1 — — — — — —
Domestic arboviral diseases § ,¶:
 California serogroup virus disease — — 1 55 62 55 67 80
 Eastern equine encephalitis virus disease — — 0 4 4 4 8 21
 Powassan virus disease — — 0 6 2 7 1 1
 St. Louis encephalitis virus disease — — 0 12 13 9 10 13
 Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
 serotype b — 7 0 35 30 22 29 9
 nonserotype b — 83 3 236 244 199 175 135
 unknown serotype 2 97 4 178 163 180 179 217 FL (1), TN (1)
Hansen disease§ 1 17 2 103 80 101 66 87 PA (1)
Hantavirus pulmonary syndrome§ — 2 1 18 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 5 55 5 242 330 292 288 221 MO (2), TN (1), AR (1), CA (1)
HIV infection, pediatric (age <13 yrs)†† — — 1 — — — — 380
Influenza-associated pediatric mortality§,§§ — 53 2 359 90 77 43 45
Listeriosis 4 229 12 852 759 808 884 896 DE (1), FL (2), CA (1)
Measles¶¶ — 26 4 67 140 43 55 66
Meningococcal disease, invasive***:
 A, C, Y, and W-135 — 121 6 301 330 325 318 297
 serogroup B — 51 4 174 188 167 193 156
 other serogroup — 5 0 23 38 35 32 27
 unknown serogroup 5 176 12 482 616 550 651 765 MO (1), KS (1), FL (1), CA (2)
Mumps 52 1,760 35 2,069 454 800 6,584 314 NY (5), NYC (45), PA (1), IA (1)
Novel influenza A virus infections††† — 1 0 43,771 2 4 NN NN
Plague — — 0 8 3 7 17 8
Poliomyelitis, paralytic — — — 1 — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 4 0 9 8 12 21 16
Q fever, total§,§§§ — 34 4 112 120 171 169 136
 acute — 25 2 92 106 — — —
 chronic — 9 0 20 14 — — —
Rabies, human — — 0 4 2 1 3 2
Rubella¶¶¶ — 2 0 3 16 12 11 11
Rubella, congenital syndrome — — 0 1 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ 2 79 2 162 157 132 125 129 CT (1), NV (1)
Syphilis, congenital (age <1 yr)†††† — 67 7 424 431 430 349 329
Tetanus — — 0 18 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 1 39 2 74 71 92 101 90 CA (1)
Trichinellosis — 1 0 13 39 5 15 16
Tularemia — 11 5 93 123 137 95 154
Typhoid fever — 139 6 399 449 434 353 324
Vancomycin-intermediate Staphylococcus aureus§ 3 38 1 77 63 37 6 2 MO (3)
Vancomycin-resistant Staphylococcus aureus§ — 1 — — — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 7 117 6 790 588 549 NN NN MD (1), VA (1), FL (4), CA (1)
Viral hemorrhagic fever§§§§ — 1 — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Jose Aponte  Michael S. Wodajo
Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 


























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week 
ending June 12, 2010 (23rd week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Incidence data for reporting years 2009 and 2010 are provisional, whereas data for 2005 through 2008 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/ncphi/disss/nndss/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 286 influenza-associated pediatric 
deaths associated with 2009 influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 278 influenza-associated pediatric deaths occurring during the 
2009–10 influenza season have been reported. A total of 133 influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
 ¶¶ No measles cases were reported for the current week.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009.   During 2009, three cases of novel 
influenza A virus infections, unrelated to the 2009 pandemic influenza A (H1N1) virus, were reported to CDC.  The one case of novel influenza A virus infection reported to CDC during 
2010 was identified as swine influenza A (H3N2) virus and is unrelated to pandemic influenza A (H1N1) virus.
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ No rubella cases were reported for the current week.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
 §§§§ There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 13,156 22,517 27,358 456,353 554,311 61 120 284 2,155 2,257
New England 1,081 742 1,396 16,954 17,539 — 5 35 111 153
Connecticut 350 213 736 4,023 5,192 — 0 31 31 38
Maine† 50 48 75 1,094 1,127 — 1 4 25 17
Massachusetts 607 393 767 8,961 8,216 — 1 15 — 43
New Hampshire 55 36 114 865 928 — 1 6 25 24
Rhode Island† — 70 130 1,490 1,544 — 0 8 7 2
Vermont† 19 23 63 521 532 — 1 9 23 29
Mid. Atlantic 2,886 3,144 4,619 72,731 69,963 9 14 38 242 260
New Jersey 483 440 624 9,620 11,119 — 0 5 — 16
New York (Upstate) 670 634 2,530 14,482 12,823 4 3 16 59 57
New York City 1,310 1,182 2,144 28,531 26,590 — 1 5 23 36
Pennsylvania 423 865 1,056 20,098 19,431 5 8 19 160 151
E.N. Central 644 3,411 4,413 61,208 91,016 11 28 73 490 556
Illinois — 1,034 1,322 9,334 27,741 — 3 8 65 55
Indiana — 302 602 5,293 10,471 — 4 11 60 117
Michigan 517 885 1,416 21,725 21,286 1 6 11 119 99
Ohio 122 940 1,073 18,855 21,852 10 7 16 154 150
Wisconsin 5 372 493 6,001 9,666 — 8 39 92 135
W.N. Central 330 1,309 1,711 27,602 31,702 14 20 59 348 306
Iowa 26 177 252 4,366 4,416 — 4 13 74 75
Kansas 52 191 571 4,182 4,492 2 2 6 41 32
Minnesota — 263 337 5,178 6,609 — 5 31 94 64
Missouri 210 492 638 11,016 11,711 5 3 12 60 57
Nebraska† — 95 237 2,087 2,384 3 2 9 42 31
North Dakota 42 32 93 773 747 4 0 18 10 1
South Dakota — 49 82 — 1,343 — 2 10 27 46
S. Atlantic 2,803 4,174 6,098 75,509 114,558 8 19 50 376 385
Delaware 37 87 145 1,863 2,117 — 0 2 2 1
District of Columbia 104 112 178 2,291 3,150 — 0 1 2 4
Florida 664 1,402 1,669 31,644 33,346 5 8 24 153 120
Georgia — 410 1,323 3,098 18,694 — 6 31 140 155
Maryland† 466 448 1,031 9,485 10,008 1 0 3 12 22
North Carolina — 586 1,291 — 19,560 — 1 11 11 32
South Carolina† 727 523 1,331 12,115 12,288 2 1 7 20 20
Virginia† 805 598 924 13,454 13,657 — 1 7 30 26
West Virginia — 67 137 1,559 1,738 — 0 2 6 5
E.S. Central 1,513 1,761 2,268 35,818 41,012 2 4 10 83 65
Alabama† 450 474 629 10,099 12,196 — 1 5 34 22
Kentucky 351 312 642 6,807 4,584 2 1 4 26 16
Mississippi 238 424 640 7,505 10,907 — 0 3 4 5
Tennessee† 474 561 734 11,407 13,325 — 1 5 19 22
W.S. Central 1,763 2,914 5,784 63,451 70,890 1 8 40 112 119
Arkansas† 228 228 402 2,722 6,498 — 1 5 13 12
Louisiana — 367 1,055 2,922 13,816 — 1 6 16 13
Oklahoma — 252 2,727 6,386 3,224 — 2 9 22 32
Texas† 1,535 2,051 3,212 51,421 47,352 1 5 30 61 62
Mountain 428 1,559 2,118 29,883 31,538 — 9 25 176 172
Arizona 94 484 713 9,437 11,330 — 0 3 12 14
Colorado — 428 709 7,775 5,511 — 2 10 50 43
Idaho† 37 64 185 1,228 1,583 — 1 7 29 19
Montana† 21 57 76 1,320 1,414 — 1 4 25 14
Nevada† 218 174 478 4,316 4,316 — 0 2 5 7
New Mexico† — 163 453 2,213 3,708 — 2 8 29 52
Utah 48 117 175 2,748 2,815 — 1 4 19 10
Wyoming† 10 37 70 846 861 — 0 2 7 13
Pacific 1,708 3,481 5,350 73,197 86,093 16 13 27 217 241
Alaska — 105 145 2,571 2,365 — 0 1 1 2
California 1,444 2,677 4,406 57,999 66,030 11 8 20 130 125
Hawaii — 117 158 2,466 2,776 — 0 0 — 1
Oregon — 173 468 1,367 4,878 — 2 10 54 83
Washington 264 393 638 8,794 10,044 5 1 8 32 30
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 2 27 82 60 — 0 0 — —
Puerto Rico — 113 329 2,229 3,261 N 0 0 N N
U.S. Virgin Islands — 9 16 132 241 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Dengue Virus Infection
Reporting area
Dengue Fever† Dengue Hemorrhagic Fever§
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 0 8 39 NN — 0 0 — NN
New England — 0 1 1 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine¶ — 0 1 1 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island¶ — 0 0 — NN — 0 0 — NN
Vermont¶ — 0 0 — NN — 0 0 — NN
Mid. Atlantic — 0 3 12 NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 2 8 NN — 0 0 — NN
Pennsylvania — 0 2 4 NN — 0 0 — NN
E.N. Central — 0 2 5 NN — 0 0 — NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 0 — NN — 0 0 — NN
Michigan — 0 0 — NN — 0 0 — NN
Ohio — 0 2 5 NN — 0 0 — NN
Wisconsin — 0 0 — NN — 0 0 — NN
W.N. Central — 0 1 1 NN — 0 0 — NN
Iowa — 0 0 — NN — 0 0 — NN
Kansas — 0 0 — NN — 0 0 — NN
Minnesota — 0 0 — NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska¶ — 0 0 — NN — 0 0 — NN
North Dakota — 0 1 1 NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 0 2 14 NN — 0 0 — NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 0 2 13 NN — 0 0 — NN
Georgia — 0 1 1 NN — 0 0 — NN
Maryland¶ — 0 0 — NN — 0 0 — NN
North Carolina — 0 0 — NN — 0 0 — NN
South Carolina¶ — 0 0 — NN — 0 0 — NN
Virginia¶ — 0 0 — NN — 0 0 — NN
West Virginia — 0 0 — NN — 0 0 — NN
E.S. Central — 0 0 — NN — 0 0 — NN
Alabama¶ — 0 0 — NN — 0 0 — NN
Kentucky — 0 0 — NN — 0 0 — NN
Mississippi — 0 0 — NN — 0 0 — NN
Tennessee¶ — 0 0 — NN — 0 0 — NN
W.S. Central — 0 0 — NN — 0 0 — NN
Arkansas¶ — 0 0 — NN — 0 0 — NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 0 — NN — 0 0 — NN
Texas¶ — 0 0 — NN — 0 0 — NN
Mountain — 0 1 2 NN — 0 0 — NN
Arizona — 0 0 — NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho¶ — 0 0 — NN — 0 0 — NN
Montana¶ — 0 0 — NN — 0 0 — NN
Nevada¶ — 0 1 1 NN — 0 0 — NN
New Mexico¶ — 0 1 1 NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming¶ — 0 0 — NN — 0 0 — NN
Pacific — 0 2 4 NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 1 1 NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 2 3 NN — 0 0 — NN
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 0 82 925 NN — 0 3 22 NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Dengue Fever includes cases that meet criteria for Dengue Fever with hemorrhage.
§ DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23 725 
TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 14 8 176 108 187 9 11 308 69 163 — 2 34 11 58
New England — 0 4 3 6 1 2 21 14 28 — 0 1 1 2
Connecticut — 0 0 — — — 0 13 — — — 0 0 — —
Maine§ — 0 1 2 1 — 0 3 5 6 — 0 0 — —
Massachusetts — 0 0 — — — 0 0 — — — 0 0 — —
New Hampshire — 0 1 1 1 1 0 3 6 7 — 0 1 1 1
Rhode Island§ — 0 4 — 4 — 0 20 3 15 — 0 0 — 1
Vermont§ — 0 1 — — — 0 0 — — — 0 0 — —
Mid. Atlantic 1 3 15 11 35 8 3 27 28 59 — 0 4 1 14
New Jersey — 0 8 — 23 — 0 7 1 21 — 0 0 — —
New York (Upstate) 1 1 15 6 7 8 2 20 27 37 — 0 2 1 1
New York City — 0 2 4 1 — 0 1 — 1 — 0 0 — 1
Pennsylvania — 0 5 1 4 — 0 1 — — — 0 3 — 12
E.N. Central — 0 7 2 37 — 2 23 19 72 — 0 6 2 28
Illinois — 0 4 — 17 — 0 1 — 2 — 0 1 — 3
Indiana — 0 0 — — — 0 0 — — — 0 3 1 15
Michigan — 0 1 — 1 — 0 0 — — — 0 0 — —
Ohio — 0 2 — 3 — 0 0 — 1 — 0 1 — —
Wisconsin — 0 3 2 16 — 2 22 19 69 — 0 3 1 10
W.N. Central 8 2 23 30 35 — 0 261 — — — 0 30 3 4
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 1 — 3 — 0 1 — — — 0 0 — —
Minnesota — 0 6 — — — 0 261 — — — 0 30 — 2
Missouri 8 1 22 29 32 — 0 2 — — — 0 4 3 2
Nebraska§ — 0 1 1 — — 0 1 — — — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 4 3 14 40 42 — 0 2 7 3 — 0 2 — —
Delaware — 0 3 7 6 — 0 1 1 — — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida 2 0 1 4 4 — 0 1 — — — 0 0 — —
Georgia — 0 2 3 8 — 0 1 1 1 — 0 0 — —
Maryland§ — 0 4 5 16 — 0 1 3 2 — 0 0 — —
North Carolina — 0 3 7 — — 0 1 1 — — 0 0 — —
South Carolina§ — 0 1 — 3 — 0 0 — — — 0 0 — —
Virginia§ 2 1 13 14 5 — 0 1 1 — — 0 2 — —
West Virginia — 0 1 — — — 0 0 — — — 0 1 — —
E.S. Central 1 1 11 15 28 — 0 1 1 1 — 0 5 4 10
Alabama§ — 0 3 2 — — 0 1 — — — 0 0 — —
Kentucky — 0 2 2 2 — 0 0 — — — 0 0 — —
Mississippi — 0 2 — 1 — 0 0 — — — 0 0 — —
Tennessee§ 1 1 10 11 25 — 0 1 1 1 — 0 5 4 10
W.S. Central — 0 141 7 2 — 0 23 — — — 0 0 — —
Arkansas§ — 0 34 — 1 — 0 6 — — — 0 0 — —
Louisiana — 0 0 — — — 0 0 — — — 0 0 — —
Oklahoma — 0 105 6 1 — 0 16 — — — 0 0 — —
Texas§ — 0 2 1 — — 0 1 — — — 0 0 — —
Mountain — 0 0 — — — 0 0 — — — 0 1 — —
Arizona — 0 0 — — — 0 0 — — — 0 1 — —
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 — 2 — 0 1 — — — 0 1 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 — 2 — 0 1 — — — 0 1 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Cumulative total E. ewingii cases reported as of this week = 0.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 172 345 662 6,666 6,965 3,045 5,397 6,935 102,370 132,896 23 56 171 1,237 1,421
New England 4 26 65 314 556 142 92 197 2,272 2,100 1 3 21 36 88
Connecticut — 6 15 94 107 69 46 170 1,044 960 1 0 15 18 23
Maine§ 4 4 13 81 78 4 3 11 92 62 — 0 2 4 12
Massachusetts — 9 36 — 244 65 39 81 919 861 — 0 8 — 43
New Hampshire — 3 11 54 50 4 2 7 70 49 — 0 2 7 5
Rhode Island§ — 1 7 19 23 — 6 19 120 145 — 0 2 4 1
Vermont§ — 4 14 66 54 — 1 17 27 23 — 0 1 3 4
Mid. Atlantic 29 63 112 1,167 1,316 595 635 941 14,335 13,415 6 12 34 272 250
New Jersey — 7 15 89 186 130 92 133 2,050 2,071 — 2 7 38 48
New York (Upstate) 18 24 84 442 474 88 101 422 2,250 2,272 2 3 20 75 58
New York City 4 16 25 345 361 282 215 396 5,266 4,831 — 2 6 58 30
Pennsylvania 7 15 37 291 295 95 208 277 4,769 4,241 4 4 9 101 114
E.N. Central 13 51 92 1,012 1,082 158 1,070 1,536 17,040 28,633 — 8 18 172 232
Illinois — 12 22 208 230 — 347 441 2,305 9,208 — 2 9 45 87
Indiana — 6 14 99 95 — 85 183 1,443 3,425 — 1 5 28 46
Michigan 4 13 25 256 266 135 248 502 6,084 6,792 — 0 4 17 12
Ohio 9 16 28 356 332 23 314 372 5,822 6,811 — 2 6 52 49
Wisconsin — 7 23 93 159 — 90 185 1,386 2,397 — 1 5 30 38
W.N. Central 11 27 165 611 600 81 272 367 5,525 6,682 4 3 24 82 77
Iowa 4 6 15 111 118 3 31 46 688 753 — 0 1 1 —
Kansas 1 4 14 91 56 6 40 83 815 1,117 — 0 2 8 10
Minnesota — 0 135 136 137 — 41 64 762 1,066 — 0 17 23 18
Missouri 4 9 27 156 187 72 123 172 2,757 2,903 2 1 6 36 32
Nebraska§ 1 3 9 78 64 — 22 55 448 620 1 0 3 8 12
North Dakota 1 0 8 10 4 — 2 11 55 50 1 0 4 6 5
South Dakota — 1 10 29 34 — 3 16 — 173 — 0 0 — —
S. Atlantic 64 74 143 1,619 1,490 828 1,260 1,774 20,937 33,389 10 14 27 324 400
Delaware — 0 3 12 13 4 19 37 422 367 — 0 1 4 3
District of Columbia — 1 4 10 31 60 43 86 863 1,239 — 0 1 — 1
Florida 51 37 87 820 780 226 379 482 8,389 9,497 8 3 9 94 134
Georgia — 13 52 382 313 — 135 494 1,108 6,271 — 3 9 79 75
Maryland§ 2 6 12 131 113 141 128 237 2,709 2,638 1 1 6 25 46
North Carolina N 0 0 N N — 210 386 — 6,485 — 1 6 20 51
South Carolina§ 2 2 7 49 41 207 159 394 3,569 3,696 — 2 7 49 33
Virginia§ 9 8 36 199 181 190 164 271 3,680 2,946 1 2 5 42 39
West Virginia — 1 5 16 18 — 8 19 197 250 — 0 5 11 18
E.S. Central 3 7 22 105 160 388 482 655 9,628 11,661 1 3 12 84 96
Alabama§ — 4 13 59 74 121 135 187 2,909 3,375 — 0 2 10 26
Kentucky N 0 0 N N 75 88 156 1,714 1,348 — 0 5 14 10
Mississippi N 0 0 N N 88 127 198 2,085 3,327 — 0 2 7 6
Tennessee§ 3 3 18 46 86 104 145 206 2,920 3,611 1 2 10 53 54
W.S. Central — 9 18 135 169 446 842 1,554 16,437 20,436 — 2 20 60 63
Arkansas§ — 2 9 41 51 86 72 139 798 1,968 — 0 3 10 11
Louisiana — 3 10 52 77 — 108 343 910 4,478 — 0 2 12 11
Oklahoma — 3 10 42 41 — 79 616 1,671 1,128 — 1 15 33 38
Texas§ N 0 0 N N 360 568 964 13,058 12,862 — 0 2 5 3
Mountain 1 32 64 610 560 60 172 266 3,402 3,896 1 5 14 155 132
Arizona — 3 7 59 86 7 63 109 1,098 1,245 — 2 10 60 45
Colorado — 12 26 282 158 — 50 127 1,046 1,197 — 1 6 39 37
Idaho§ 1 4 10 85 56 — 2 8 35 42 1 0 2 8 2
Montana§ — 3 11 54 44 — 2 6 50 39 — 0 1 2 1
Nevada§ — 2 11 25 37 44 27 94 777 771 — 0 2 5 11
New Mexico§ — 1 8 29 51 — 18 41 238 440 — 1 5 23 18
Utah — 5 13 61 103 7 6 14 143 134 — 0 4 13 17
Wyoming§ — 1 5 15 25 2 1 7 15 28 — 0 2 5 1
Pacific 47 53 133 1,093 1,032 347 550 664 12,794 12,684 — 2 9 52 83
Alaska — 2 7 37 31 — 23 36 591 369 — 0 2 11 7
California 32 34 61 699 728 303 458 557 10,746 10,458 — 0 3 6 31
Hawaii — 0 2 — 8 — 10 24 265 289 — 0 2 — 17
Oregon 1 9 17 204 141 — 13 43 106 501 — 1 5 32 25
Washington 14 8 75 153 124 44 43 84 1,086 1,067 — 0 4 3 3
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 1 — 0 3 5 5 — 0 0 — —
Puerto Rico — 1 10 10 67 — 4 24 101 96 — 0 1 1 2
U.S. Virgin Islands — 0 0 — — — 1 4 25 76 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 17 33 68 584 857 27 57 203 1,153 1,516 9 14 43 316 333
New England — 1 5 19 45 — 1 3 19 26 — 1 5 11 24
Connecticut — 0 2 12 10 — 0 3 4 5 — 1 4 11 18
Maine† — 0 1 3 1 — 0 2 9 6 — 0 1 — —
Massachusetts — 1 4 — 24 — 0 2 — 12 — 0 1 — 5
New Hampshire — 0 1 — 5 — 0 2 5 3 — 0 0 — —
Rhode Island† — 0 4 4 3 — 0 0 — — — 0 0 — —
Vermont† — 0 0 — 2 — 0 1 1 — — 0 0 — 1
Mid. Atlantic 1 4 10 82 118 1 5 10 121 178 3 2 4 43 45
New Jersey — 0 4 8 35 — 1 4 25 57 — 0 2 5 6
New York (Upstate) — 1 3 25 21 1 1 6 24 32 2 1 3 26 20
New York City — 1 5 25 32 — 1 4 37 33 — 0 1 — 1
Pennsylvania 1 1 6 24 30 — 1 5 35 56 1 0 3 12 18
E.N. Central 2 4 19 79 130 6 8 14 167 218 — 2 6 59 39
Illinois — 1 13 14 48 — 2 6 27 50 — 0 1 — 3
Indiana — 0 4 8 9 — 1 5 19 38 — 0 3 10 5
Michigan 1 1 4 26 34 1 2 6 48 64 — 1 6 45 13
Ohio 1 0 4 15 24 5 2 4 54 54 — 0 3 3 16
Wisconsin — 0 3 16 15 — 0 3 19 12 — 0 1 1 2
W.N. Central 1 1 10 24 52 2 3 15 59 54 — 0 11 12 5
Iowa — 0 3 4 15 — 1 3 9 12 — 0 4 1 2
Kansas — 0 2 7 5 — 0 2 3 4 — 0 0 — 1
Minnesota — 0 8 1 12 — 0 13 2 10 — 0 9 3 —
Missouri 1 0 3 11 9 2 1 5 36 17 — 0 1 7 —
Nebraska† — 0 3 1 9 — 0 2 9 10 — 0 1 1 2
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — 2 — 0 1 — 1 — 0 1 — —
S. Atlantic 4 7 14 128 192 10 16 39 342 404 2 3 8 64 91
Delaware — 0 1 5 3 — 1 2 15 16 U 0 0 U U
District of Columbia — 0 1 1 1 — 0 2 2 4 — 0 1 2 —
Florida 4 3 8 51 88 8 5 11 139 141 2 1 4 24 16
Georgia — 1 3 16 19 — 3 7 62 62 — 0 2 5 20
Maryland† — 0 4 10 18 — 1 6 24 42 — 0 3 12 15
North Carolina — 0 3 11 32 — 1 4 4 58 — 0 4 9 17
South Carolina† — 1 4 19 17 1 1 4 24 20 — 0 0 — 1
Virginia† — 1 3 14 14 1 2 14 43 38 — 0 2 6 6
West Virginia — 0 2 1 — — 0 19 29 23 — 0 3 6 16
E.S. Central 1 1 3 18 19 4 6 13 125 163 — 2 7 53 46
Alabama† — 0 1 4 6 — 1 5 27 48 — 0 2 2 5
Kentucky — 0 2 9 3 2 2 6 39 41 — 1 5 37 26
Mississippi — 0 1 — 5 — 0 3 12 12 — 0 0 — —
Tennessee† 1 0 2 5 5 2 2 6 47 62 — 0 4 14 15
W.S. Central 3 3 19 66 79 3 9 109 165 255 — 1 14 23 23
Arkansas† — 0 3 — 5 — 1 4 18 32 — 0 1 — 1
Louisiana — 0 1 4 2 — 1 5 18 27 — 0 1 2 4
Oklahoma — 0 3 — 1 — 1 19 29 48 — 0 12 12 3
Texas† 3 3 18 62 71 3 5 87 100 148 — 0 4 9 15
Mountain — 3 8 63 65 — 2 6 39 65 1 1 4 18 24
Arizona — 1 5 34 26 — 0 3 14 28 — 0 0 — —
Colorado — 1 4 11 19 — 0 2 1 11 — 0 3 2 13
Idaho† — 0 1 3 — — 0 2 4 2 — 0 2 6 1
Montana† — 0 1 4 4 — 0 1 — — — 0 0 — 1
Nevada† — 0 2 6 7 — 1 3 16 13 1 0 1 2 2
New Mexico† — 0 1 3 6 — 0 1 2 4 — 0 2 5 5
Utah — 0 2 2 3 — 0 1 2 4 — 0 1 3 2
Wyoming† — 0 1 — — — 0 1 — 3 — 0 0 — —
Pacific 5 5 16 105 157 1 6 20 116 153 3 1 6 33 36
Alaska — 0 0 — 2 — 0 1 1 2 — 0 2 — —
California 4 4 15 85 118 1 4 16 81 110 1 0 4 13 17
Hawaii — 0 2 — 6 — 0 1 — 4 — 0 0 — —
Oregon — 0 2 10 8 — 1 4 18 19 — 0 3 10 9
Washington 1 0 2 10 23 — 0 4 16 18 2 0 6 10 10
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 6 10 13 — 1 6 22 43 — 1 5 19 30
Puerto Rico — 0 2 2 15 — 0 5 7 14 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 36 57 174 794 818 256 388 2,345 4,719 8,227 12 25 87 425 496
New England — 3 18 22 35 9 109 857 743 3,051 — 1 4 7 22
Connecticut — 1 5 11 10 — 29 295 232 1,202 — 0 3 1 1
Maine† — 0 3 3 — 8 14 76 164 81 — 0 1 3 1
Massachusetts — 0 9 — 22 — 35 401 — 1,245 — 0 3 — 15
New Hampshire — 0 3 2 1 1 19 95 294 445 — 0 1 1 1
Rhode Island† — 0 4 5 1 — 1 29 10 17 — 0 1 1 2
Vermont† — 0 1 1 1 — 4 45 43 61 — 0 1 1 2
Mid. Atlantic 6 19 73 182 225 186 152 999 2,657 3,171 2 7 17 126 143
New Jersey — 2 14 3 51 — 37 430 606 1,418 — 1 5 1 40
New York (Upstate) 4 5 29 61 64 116 56 577 665 683 2 1 4 29 20
New York City — 3 19 34 34 — 10 58 3 237 — 3 12 72 63
Pennsylvania 2 6 25 84 76 70 68 475 1,383 833 — 1 4 24 20
E.N. Central 6 10 41 141 159 2 18 258 218 586 2 2 12 42 63
Illinois — 1 11 7 22 — 1 12 6 30 — 1 7 19 27
Indiana — 1 5 10 18 — 1 6 10 20 — 0 4 2 9
Michigan — 3 13 30 27 1 1 9 7 9 — 0 3 5 10
Ohio 6 5 17 81 69 — 1 5 6 6 2 0 6 15 14
Wisconsin — 1 6 13 23 1 17 239 189 521 — 0 2 1 3
W.N. Central 2 2 19 34 28 — 3 1,395 16 79 1 1 11 22 25
Iowa — 0 3 2 8 — 0 14 8 38 — 0 1 6 5
Kansas — 0 1 3 3 — 0 2 4 9 — 0 1 3 2
Minnesota — 0 16 10 1 — 0 1,380 — 26 — 0 11 3 10
Missouri 1 1 5 12 10 — 0 1 1 1 — 0 1 3 5
Nebraska† 1 0 2 3 5 — 0 3 3 4 1 0 2 7 2
North Dakota — 0 1 2 1 — 0 15 — — — 0 1 — —
South Dakota — 0 1 2 — — 0 0 — 1 — 0 0 — 1
S. Atlantic 12 11 24 172 168 54 59 258 938 1,223 3 6 15 110 147
Delaware — 0 5 5 1 9 12 65 233 287 — 0 1 2 1
District of Columbia — 0 5 2 6 — 0 7 3 16 — 0 3 5 5
Florida 4 3 10 69 64 — 2 11 24 13 — 2 7 47 36
Georgia — 1 4 21 23 — 0 6 3 18 — 0 6 2 31
Maryland† 4 3 12 40 32 10 28 134 415 607 — 1 13 22 39
North Carolina — 0 5 2 25 — 0 7 12 47 — 0 3 5 15
South Carolina† 1 0 2 4 3 1 1 3 14 16 — 0 1 3 1
Virginia† 3 1 6 24 14 34 14 79 219 186 3 1 5 24 18
West Virginia — 0 3 5 — — 0 33 15 33 — 0 2 — 1
E.S. Central 3 2 12 43 45 1 1 4 18 9 1 0 4 10 15
Alabama† — 0 2 4 8 — 0 1 — 1 1 0 3 2 3
Kentucky — 0 3 9 18 — 0 1 1 1 — 0 3 3 5
Mississippi — 0 2 2 2 — 0 0 — — — 0 1 — —
Tennessee† 3 1 9 28 17 1 1 4 17 7 — 0 1 5 7
W.S. Central — 2 14 36 45 — 3 44 26 40 — 2 31 47 14
Arkansas† — 0 1 6 3 — 0 0 — — — 0 1 1 1
Louisiana — 0 3 1 5 — 0 0 — — — 0 1 — 3
Oklahoma — 0 4 5 3 — 0 2 — — — 0 1 3 —
Texas† — 1 10 24 34 — 3 42 26 40 — 1 30 43 10
Mountain 4 3 8 47 47 1 0 4 6 18 1 1 6 15 14
Arizona 2 1 4 19 22 1 0 1 1 1 1 0 2 7 1
Colorado — 0 4 2 4 — 0 1 1 — — 0 3 2 9
Idaho† — 0 2 — 1 — 0 3 2 6 — 0 1 — 1
Montana† — 0 1 2 4 — 0 1 — 1 — 0 3 1 1
Nevada† 2 0 2 14 6 — 0 2 — 6 — 0 1 2 —
New Mexico† — 0 2 2 1 — 0 1 1 — — 0 0 — —
Utah — 0 4 7 8 — 0 1 1 4 — 0 1 3 2
Wyoming† — 0 2 1 1 — 0 1 — — — 0 0 — —
Pacific 3 4 19 117 66 3 4 10 97 50 2 2 19 46 53
Alaska — 0 0 — 1 — 0 1 1 3 — 0 1 2 1
California 3 3 19 107 52 3 3 9 68 28 2 1 13 32 40
Hawaii — 0 0 — 1 N 0 0 N N — 0 0 — 1
Oregon — 0 3 3 6 — 1 4 27 17 — 0 1 4 6
Washington — 0 4 7 6 — 0 3 1 2 — 0 5 8 5
American Samoa — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — — N 0 0 N N — 0 2 1 1
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 5 16 43 353 503 109 264 1,751 4,656 6,017 22 67 147 1,101 2,290
New England — 0 2 5 16 — 7 21 33 304 1 5 24 103 142
Connecticut — 0 2 — 2 — 1 4 14 14 1 1 22 53 59
Maine§ — 0 1 2 2 — 0 8 7 55 — 1 4 25 22
Massachusetts — 0 1 — 9 — 3 12 — 181 — 0 0 — —
New Hampshire — 0 1 — 1 — 0 4 4 39 — 0 3 3 17
Rhode Island§ — 0 1 — 1 — 0 8 5 8 — 0 5 3 17
Vermont§ — 0 1 3 1 — 0 1 3 7 — 1 5 19 27
Mid. Atlantic — 1 4 34 58 15 19 42 303 508 9 10 25 272 259
New Jersey — 0 2 8 9 — 3 10 41 114 — 0 0 — —
New York (Upstate) — 0 3 8 11 8 6 27 113 75 9 9 22 208 157
New York City — 0 2 8 12 3 0 11 16 46 — 0 11 64 2
Pennsylvania — 0 2 10 26 4 7 22 133 273 — 0 0 — 100
E.N. Central — 2 7 53 93 47 56 105 1,127 1,212 5 2 19 45 62
Illinois — 0 4 7 22 — 10 29 164 295 — 1 9 16 19
Indiana — 0 2 11 23 — 6 16 79 139 — 0 5 — 13
Michigan — 0 5 9 12 13 18 41 353 245 1 1 6 17 19
Ohio — 1 2 17 22 34 19 49 506 461 4 0 5 12 11
Wisconsin — 0 2 9 14 — 2 12 25 72 — 0 0 — —
W.N. Central 2 2 6 29 39 7 25 627 366 972 5 6 18 99 171
Iowa — 0 3 6 6 — 5 17 127 100 — 0 4 7 14
Kansas 1 0 2 3 6 — 3 12 53 103 — 1 4 22 46
Minnesota — 0 2 2 8 — 0 601 6 178 — 0 9 14 20
Missouri 1 0 3 14 13 2 12 35 124 493 4 1 5 28 17
Nebraska§ — 0 2 4 4 1 2 5 38 87 — 1 6 24 47
North Dakota — 0 1 — — 4 0 12 4 2 1 0 7 4 4
South Dakota — 0 2 — 2 — 1 6 14 9 — 0 4 — 23
S. Atlantic 1 2 7 71 100 15 23 63 448 664 — 29 58 438 1,029
Delaware — 0 1 1 2 — 0 2 — 6 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 2 3 — 0 0 — —
Florida 1 1 5 37 30 6 6 29 128 230 — 0 21 46 161
Georgia — 0 1 6 18 — 3 8 78 121 — 5 14 — 199
Maryland§ — 0 1 3 5 — 2 8 45 55 — 7 15 149 163
North Carolina — 0 2 5 25 — 1 9 — 97 — 4 17 — 213
South Carolina§ — 0 1 6 6 6 5 20 128 77 — 0 0 — —
Virginia§ — 0 2 11 10 3 4 15 59 70 — 10 26 210 243
West Virginia — 0 2 2 4 — 0 6 8 5 — 2 6 33 50
E.S. Central — 0 4 19 18 3 15 31 316 352 — 2 7 49 77
Alabama§ — 0 2 4 5 1 4 16 87 132 — 0 4 17 —
Kentucky — 0 2 8 3 — 4 15 116 103 — 0 2 3 25
Mississippi — 0 1 2 2 1 1 6 22 37 — 0 1 — 1
Tennessee§ — 0 2 5 8 1 4 10 91 80 — 1 6 29 51
W.S. Central — 1 9 39 41 13 68 753 1,155 1,103 — 8 40 17 404
Arkansas§ — 0 2 5 5 — 5 29 43 121 — 0 10 11 27
Louisiana — 0 3 8 10 — 1 7 14 80 — 0 0 — —
Oklahoma — 0 7 12 2 — 0 41 11 13 — 0 15 6 4
Texas§ — 0 7 14 24 13 61 681 1,087 889 — 6 30 — 373
Mountain — 1 4 27 40 1 18 41 400 457 — 1 8 18 47
Arizona — 0 2 7 8 — 6 13 159 93 — 0 5 — —
Colorado — 0 3 8 11 — 3 13 48 120 — 0 0 — —
Idaho§ — 0 1 4 5 1 1 19 71 42 — 0 2 1 —
Montana§ — 0 1 1 5 — 1 6 12 11 — 0 4 2 13
Nevada§ — 0 1 4 3 — 0 6 7 6 — 0 1 — —
New Mexico§ — 0 1 2 3 — 1 6 33 31 — 0 3 5 15
Utah — 0 1 1 1 — 3 8 68 137 — 0 2 — 2
Wyoming§ — 0 1 — 4 — 0 2 2 17 — 0 3 10 17
Pacific 2 3 16 76 98 8 31 186 508 445 2 3 12 60 99
Alaska — 0 2 1 3 — 0 6 12 27 — 0 2 11 9
California 2 2 13 51 63 — 19 162 312 180 2 3 11 45 89
Hawaii — 0 2 — 3 — 0 4 — 16 — 0 0 — —
Oregon — 0 5 15 20 1 5 12 119 91 — 0 2 4 1
Washington — 0 7 9 9 7 4 24 65 131 — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — 1 — 0 0 — —
Puerto Rico — 0 1 — — — 0 0 — 1 — 1 3 21 21
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 514 900 1,521 11,951 15,893 32 67 195 1,027 1,513 171 263 523 5,195 7,107
New England 2 20 169 309 1,184 — 2 30 32 133 — 3 28 34 116
Connecticut — 0 164 164 430 — 0 18 18 67 — 0 23 23 43
Maine§ 2 2 7 37 48 — 0 2 3 9 — 0 2 3 2
Massachusetts — 14 47 — 456 — 0 6 — 35 — 1 27 — 59
New Hampshire — 3 9 57 168 — 0 3 9 16 — 0 5 3 2
Rhode Island§ — 2 11 33 54 — 0 26 — — — 0 7 4 7
Vermont§ — 1 5 18 28 — 0 3 2 6 — 0 1 1 3
Mid. Atlantic 58 84 208 1,595 1,862 4 7 24 127 156 12 38 90 689 1,389
New Jersey — 15 47 196 379 — 1 5 11 46 — 6 23 108 315
New York (Upstate) 29 24 78 420 416 3 3 15 56 35 4 4 19 73 86
New York City 2 23 46 405 424 — 1 4 14 34 — 7 15 128 207
Pennsylvania 27 29 67 574 643 1 2 8 46 41 8 20 63 380 781
E.N. Central 43 74 168 1,326 2,042 4 10 29 129 270 9 28 233 796 1,368
Illinois — 24 52 423 578 — 1 6 11 84 — 9 227 524 325
Indiana — 9 31 37 227 — 1 9 13 28 — 1 5 14 37
Michigan 3 15 34 266 415 — 2 7 42 49 2 4 10 84 126
Ohio 40 25 52 514 558 4 2 11 43 42 6 9 46 138 642
Wisconsin — 8 30 86 264 — 2 11 20 67 1 4 23 36 238
W.N. Central 35 45 94 796 1,064 7 10 41 191 189 48 45 88 1,246 354
Iowa 5 7 16 127 172 — 2 14 31 45 — 0 5 22 40
Kansas 9 6 20 126 139 1 1 5 17 24 10 4 14 114 109
Minnesota — 10 32 179 238 — 2 17 31 43 — 1 6 14 30
Missouri 16 13 29 249 206 3 2 29 86 43 37 39 75 1,080 158
Nebraska§ 4 4 12 68 187 3 1 6 20 28 1 0 3 13 12
North Dakota 1 0 39 9 13 — 0 7 — 2 — 0 5 — 3
South Dakota — 2 9 38 109 — 0 12 6 4 — 0 2 3 2
S. Atlantic 135 285 503 3,238 3,738 5 12 23 185 262 28 40 73 741 1,062
Delaware — 3 9 37 30 — 0 2 1 6 — 3 10 32 37
District of Columbia — 2 6 23 40 — 0 1 2 1 — 0 3 11 14
Florida 87 131 277 1,571 1,592 1 3 7 71 75 25 11 22 301 196
Georgia — 41 105 489 648 — 1 4 21 30 — 12 23 260 285
Maryland§ 10 15 32 278 283 1 1 6 25 31 — 4 17 38 174
North Carolina — 33 90 230 507 — 1 5 4 53 — 2 26 15 208
South Carolina§ 15 18 66 246 251 1 0 3 7 12 1 1 6 31 62
Virginia§ 23 17 68 287 321 2 3 15 49 46 2 3 15 52 81
West Virginia — 4 23 77 66 — 0 5 5 8 — 0 2 1 5
E.S. Central 38 46 118 700 913 — 4 10 60 89 3 11 36 267 452
Alabama§ 3 14 40 200 283 — 1 4 16 21 — 2 10 41 86
Kentucky 19 8 18 154 176 — 1 4 6 26 2 3 26 124 119
Mississippi 3 12 42 142 216 — 0 2 9 6 — 1 4 14 16
Tennessee§ 13 13 33 204 238 — 1 8 29 36 1 5 14 88 231
W.S. Central 66 110 547 1,196 1,630 3 4 68 55 105 53 47 251 852 1,364
Arkansas§ 11 10 25 125 179 3 1 4 15 10 1 3 12 21 154
Louisiana — 19 46 254 343 — 0 3 4 13 — 3 8 77 100
Oklahoma — 10 46 146 196 — 0 27 3 6 — 7 96 133 87
Texas§ 55 58 477 671 912 — 3 41 33 76 52 34 144 621 1,023
Mountain 15 48 133 861 1,130 2 7 26 106 179 5 14 43 225 505
Arizona 3 18 50 277 392 2 1 4 24 23 4 9 38 112 359
Colorado — 11 33 213 219 — 2 11 17 73 — 2 6 40 37
Idaho§ 2 3 10 55 70 — 1 7 16 20 1 0 1 6 2
Montana§ — 2 7 39 57 — 0 7 17 8 — 0 1 4 11
Nevada§ 10 4 13 84 113 — 0 4 9 11 — 1 7 14 30
New Mexico§ — 5 40 89 120 — 1 3 13 15 — 1 8 40 55
Utah — 5 14 89 128 — 1 11 9 27 — 0 4 9 11
Wyoming§ — 1 9 15 31 — 0 2 1 2 — 0 2 — —
Pacific 122 115 299 1,930 2,330 7 9 46 142 130 13 21 64 345 497
Alaska — 1 6 33 28 — 0 1 — — — 0 2 — 1
California 88 84 227 1,401 1,783 2 5 35 69 81 13 16 51 296 389
Hawaii — 4 62 — 104 — 0 2 — 3 — 0 4 — 11
Oregon 4 8 49 252 175 2 1 11 22 11 — 1 4 24 24
Washington 30 15 61 244 240 3 3 18 51 35 — 2 9 25 72
American Samoa — 1 1 1 — — 0 0 — — — 1 1 1 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 5 — 0 0 — — — 0 0 — 2
Puerto Rico — 7 39 69 220 — 0 0 — — — 0 1 — 5
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 3 2 12 26 45 17 12 416 207 448
New England — 0 1 — 1 — 0 2 1 5
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 1 1 4
Massachusetts — 0 0 — 1 — 0 2 — 1
New Hampshire — 0 0 — — — 0 1 — —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 1 — — — 0 0 — —
Mid. Atlantic — 0 2 6 1 — 1 7 14 33
New Jersey — 0 1 — 1 — 0 3 — 26
New York (Upstate) — 0 1 1 — — 0 3 3 1
New York City — 0 1 — — — 0 2 7 2
Pennsylvania — 0 2 5 — — 0 2 4 4
E.N. Central — 0 1 — 4 — 0 7 — 36
Illinois — 0 1 — — — 0 6 — 23
Indiana — 0 0 — 3 — 0 2 — 3
Michigan — 0 1 — 1 — 0 1 — —
Ohio — 0 0 — — — 0 4 — 9
Wisconsin — 0 1 — — — 0 1 — 1
W.N. Central — 0 3 3 6 4 2 23 57 71
Iowa — 0 1 — — — 0 1 — 2
Kansas — 0 1 1 — — 0 0 — —
Minnesota — 0 1 — — — 0 1 — —
Missouri — 0 1 2 3 4 2 22 57 68
Nebraska§ — 0 2 — 3 — 0 1 — 1
North Dakota — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic 1 0 7 10 26 7 3 31 68 155
Delaware — 0 1 1 — — 0 3 5 3
District of Columbia — 0 0 — — — 0 1 — —
Florida — 0 1 1 — 1 0 3 9 2
Georgia — 0 6 5 24 — 0 0 — —
Maryland§ 1 0 1 2 — 1 0 3 4 23
North Carolina — 0 2 1 1 — 1 23 27 92
South Carolina§ — 0 1 — 1 — 0 1 2 13
Virginia§ — 0 1 — — 5 0 5 21 22
West Virginia — 0 0 — — — 0 1 — —
E.S. Central — 0 2 3 — 6 3 16 54 92
Alabama§ — 0 1 — — — 1 7 11 18
Kentucky — 0 1 2 — — 0 0 — —
Mississippi — 0 0 — — — 0 1 — 8
Tennessee§ — 0 2 1 — 6 2 13 43 66
W.S. Central — 0 3 1 1 — 1 408 12 46
Arkansas§ — 0 1 — — — 0 110 — 28
Louisiana — 0 0 — — — 0 0 — 2
Oklahoma — 0 3 — — — 0 287 8 5
Texas§ — 0 1 1 1 — 0 11 4 11
Mountain — 0 2 — 5 — 0 3 1 10
Arizona — 0 2 — 2 — 0 2 — 5
Colorado — 0 1 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 1 1 —
Montana§ — 0 1 — 3 — 0 1 — 3
Nevada§ — 0 0 — — — 0 1 — —
New Mexico§ — 0 0 — — — 0 0 — 1
Utah — 0 0 — — — 0 0 — 1
Wyoming§ — 0 1 — — — 0 1 — —
Pacific 2 0 1 3 1 — 0 0 — —
Alaska N 0 0 N N N 0 0 N N
California 2 0 1 3 1 — 0 0 — —
Hawaii N 0 0 N N N 0 0 N N
Oregon — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
American Samoa N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 93 74 448 7,458 1,775 11 49 160 1,203 1,300 107 236 413 4,522 6,069
New England 8 2 98 432 30 — 1 24 34 43 10 7 22 194 140
Connecticut 6 0 93 225 — — 0 22 22 — 3 1 10 39 29
Maine§ 2 1 6 65 8 — 0 2 6 2 — 0 3 14 1
Massachusetts — 0 1 — 2 — 0 3 — 32 6 5 12 117 96
New Hampshire — 0 7 59 — — 0 2 3 6 1 0 1 8 10
Rhode Island§ — 0 7 40 11 — 0 1 2 1 — 0 5 14 4
Vermont§ — 0 6 43 9 — 0 1 1 2 — 0 2 2 —
Mid. Atlantic 9 6 52 654 101 2 7 52 175 160 27 33 47 725 803
New Jersey — 0 7 57 — — 1 4 32 26 4 4 12 104 109
New York (Upstate) 3 3 12 101 39 1 3 19 73 76 2 2 11 43 50
New York City — 1 25 218 3 — 1 28 38 47 12 18 39 416 490
Pennsylvania 6 2 22 278 59 1 0 5 32 11 9 6 14 162 154
E.N. Central 14 16 83 1,123 407 3 8 18 196 215 1 27 44 390 647
Illinois — 0 7 51 — — 1 5 45 35 — 13 21 99 306
Indiana — 5 20 241 162 — 1 6 27 42 — 3 9 49 71
Michigan 8 1 26 372 18 — 1 6 43 44 — 4 13 98 105
Ohio 6 8 19 239 227 3 2 6 54 73 1 7 13 140 141
Wisconsin — 0 28 220 — — 1 5 27 21 — 0 2 4 24
W.N. Central 14 5 182 518 109 2 3 12 95 93 — 5 12 97 133
Iowa — 0 0 — — — 0 0 — — — 0 2 3 11
Kansas — 1 7 57 42 — 0 2 11 13 — 0 3 7 10
Minnesota — 1 179 282 20 — 1 10 42 32 — 1 5 24 33
Missouri 1 1 8 67 39 — 1 3 26 32 — 3 8 59 72
Nebraska§ 2 0 7 74 — 1 0 2 10 5 — 0 1 4 4
North Dakota 11 0 10 27 6 1 0 1 1 4 — 0 1 — 3
South Dakota — 0 3 11 2 — 0 2 5 7 — 0 0 — —
S. Atlantic 31 32 143 1,914 807 4 12 28 317 320 13 59 218 1,125 1,401
Delaware — 0 3 21 11 — 0 2 — — — 0 3 3 14
District of Columbia — 0 4 17 14 — 0 1 6 3 2 2 8 58 81
Florida 22 17 89 921 483 2 3 18 116 121 1 19 32 398 492
Georgia — 10 28 299 223 — 4 12 84 73 — 13 167 180 268
Maryland§ 6 0 25 264 4 1 1 6 32 49 4 6 12 116 118
North Carolina — 0 0 — — — 0 0 — — 3 9 31 191 235
South Carolina§ 2 0 25 298 — — 1 4 33 30 — 2 6 57 55
Virginia§ 1 0 4 36 — 1 1 4 34 29 3 4 22 119 134
West Virginia — 1 21 58 72 — 0 4 12 15 — 0 2 3 4
E.S. Central 5 7 50 699 179 — 2 8 67 76 18 20 39 368 501
Alabama§ — 0 0 — — — 0 0 — — 1 5 17 86 202
Kentucky — 2 16 101 49 — 0 2 8 7 3 1 13 52 24
Mississippi — 1 6 32 29 — 0 2 6 10 10 5 17 90 84
Tennessee§ 5 3 44 566 101 — 2 7 53 59 4 7 15 140 191
W.S. Central 2 5 88 911 70 — 6 41 145 194 26 44 72 651 1,230
Arkansas§ 1 1 8 91 34 — 0 3 10 25 6 5 14 53 85
Louisiana — 1 8 46 36 — 0 3 16 17 — 7 27 64 364
Oklahoma — 0 5 31 — — 1 5 31 30 — 1 6 27 43
Texas§ 1 0 81 743 — — 3 34 88 122 20 27 46 507 738
Mountain 6 3 82 1,045 70 — 5 12 151 182 7 8 18 154 240
Arizona 6 0 51 508 — — 2 7 69 81 3 3 10 57 113
Colorado — 0 20 294 — — 1 4 40 27 — 2 5 45 42
Idaho§ — 0 1 8 — — 0 1 4 6 — 0 1 2 3
Montana§ — 0 1 10 — — 0 1 1 — — 0 1 — —
Nevada§ — 1 4 43 27 — 0 1 4 6 4 1 10 38 47
New Mexico§ — 0 8 91 — — 0 4 13 22 — 1 4 7 20
Utah — 1 9 83 36 — 1 4 18 39 — 0 2 5 14
Wyoming§ — 0 2 8 7 — 0 1 2 1 — 0 1 — 1
Pacific 4 0 14 162 2 — 0 7 23 17 5 39 61 818 974
Alaska — 0 9 65 — — 0 5 16 10 — 0 0 — —
California 4 0 12 97 — — 0 2 7 — 4 35 56 724 866
Hawaii — 0 1 — 2 — 0 1 — 7 — 0 3 17 17
Oregon — 0 0 — — — 0 0 — — — 0 5 6 23
Washington — 0 0 — — — 0 0 — — 1 3 7 71 68
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 3 17 78 98
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending June 12, 2010, and June 13, 2009 (23rd week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox)§ Neuroinvasive Nonneuroinvasive¶
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 139 329 466 7,646 12,995 — 0 46 1 10 — 0 49 — 8
New England 2 17 36 305 551 — 0 0 — — — 0 0 — —
Connecticut — 6 20 119 270 — 0 0 — — — 0 0 — —
Maine§ — 4 15 96 92 — 0 0 — — — 0 0 — —
Massachusetts — 0 1 — 3 — 0 0 — — — 0 0 — —
New Hampshire 1 3 8 65 114 — 0 0 — — — 0 0 — —
Rhode Island§ 1 1 12 13 21 — 0 0 — — — 0 0 — —
Vermont§ — 1 10 12 51 — 0 0 — — — 0 0 — —
Mid. Atlantic 20 33 66 826 1,227 — 0 2 — — — 0 1 — —
New Jersey 1 9 30 294 259 — 0 1 — — — 0 0 — —
New York (Upstate) N 0 0 N N — 0 1 — — — 0 1 — —
New York City — 0 0 — — — 0 1 — — — 0 0 — —
Pennsylvania 19 22 52 532 968 — 0 0 — — — 0 0 — —
E.N. Central 43 107 170 2,716 4,158 — 0 4 — — — 0 3 — —
Illinois — 26 49 652 987 — 0 3 — — — 0 0 — —
Indiana§ 2 5 35 247 305 — 0 1 — — — 0 1 — —
Michigan 20 35 62 875 1,212 — 0 1 — — — 0 0 — —
Ohio 21 28 56 787 1,309 — 0 0 — — — 0 2 — —
Wisconsin — 7 57 155 345 — 0 1 — — — 0 0 — —
W.N. Central 3 13 40 294 850 — 0 5 — — — 0 11 — 3
Iowa N 0 0 N N — 0 0 — — — 0 1 — —
Kansas§ — 4 18 94 369 — 0 1 — — — 0 2 — 1
Minnesota — 0 0 — — — 0 1 — — — 0 1 — —
Missouri 3 6 16 162 409 — 0 2 — — — 0 1 — —
Nebraska§ N 0 0 N N — 0 2 — — — 0 6 — —
North Dakota — 0 26 29 38 — 0 0 — — — 0 1 — —
South Dakota — 0 7 9 34 — 0 3 — — — 0 2 — 2
S. Atlantic 28 36 94 1,168 1,596 — 0 4 — — — 0 2 — —
Delaware§ 2 0 3 15 7 — 0 0 — — — 0 0 — —
District of Columbia — 0 4 7 21 — 0 1 — — — 0 0 — —
Florida§ 16 15 57 627 815 — 0 1 — — — 0 1 — —
Georgia N 0 0 N N — 0 1 — — — 0 0 — —
Maryland§ N 0 0 N N — 0 0 — — — 0 1 — —
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina§ — 0 34 69 90 — 0 2 — — — 0 0 — —
Virginia§ 3 10 34 206 428 — 0 2 — — — 0 0 — —
West Virginia 7 8 26 244 235 — 0 0 — — — 0 0 — —
E.S. Central 4 6 28 161 340 — 0 6 1 2 — 0 4 — —
Alabama§ 4 6 27 160 337 — 0 0 — — — 0 0 — —
Kentucky N 0 0 N N — 0 1 — 1 — 0 0 — —
Mississippi — 0 1 1 3 — 0 5 1 — — 0 4 — —
Tennessee§ N 0 0 N N — 0 2 — 1 — 0 1 — —
W.S. Central 29 71 285 1,566 3,004 — 0 19 — 5 — 0 6 — 1
Arkansas§ 1 4 32 100 307 — 0 1 — 2 — 0 0 — —
Louisiana — 2 8 25 67 — 0 2 — — — 0 4 — —
Oklahoma N 0 0 N N — 0 2 — — — 0 2 — —
Texas§ 28 61 272 1,441 2,630 — 0 16 — 3 — 0 4 — 1
Mountain 10 25 48 593 1,197 — 0 12 — 1 — 0 17 — 4
Arizona — 0 0 — — — 0 4 — 1 — 0 2 — —
Colorado§ — 10 41 227 645 — 0 7 — — — 0 14 — 1
Idaho§ N 0 0 N N — 0 3 — — — 0 5 — —
Montana§ 9 2 17 117 105 — 0 1 — — — 0 1 — —
Nevada§ N 0 0 N N — 0 2 — — — 0 1 — 1
New Mexico§ 1 1 7 55 82 — 0 2 — — — 0 1 — —
Utah — 6 22 182 365 — 0 1 — — — 0 0 — 1
Wyoming§ — 0 3 12 — — 0 1 — — — 0 2 — 1
Pacific — 1 5 17 72 — 0 12 — 2 — 0 12 — —
Alaska — 0 4 17 43 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 8 — 2 — 0 6 — —
Hawaii — 0 2 — 29 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 1 — — — 0 4 — —
Washington N 0 0 N N — 0 6 — — — 0 3 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 8 12 — 0 0 — — — 0 0 — —
Puerto Rico — 5 30 103 293 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
MMWR  Morbidity and Mortality Weekly Report
734 MMWR  /  June 18, 2010  /  Vol. 59  /  No. 23
TABLE III. Deaths in 122 U.S. cities,* week ending June 12, 2010 (23rd week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 522 359 129 24 3 7 47 S. Atlantic 1,282 786 355 76 41 24 69
Boston, MA 127 83 36 3 2 3 14 Atlanta, GA 166 90 53 11 9 3 4
Bridgeport, CT 30 20 8 1 — 1 1 Baltimore, MD 153 86 43 12 7 5 12
Cambridge, MA 16 14 2 — — — 1 Charlotte, NC 98 60 30 4 2 2 4
Fall River, MA 26 18 6 2 — — 2 Jacksonville, FL 194 132 54 6 — 2 11
Hartford, CT 63 41 19 3 — — 6 Miami, FL 89 54 25 6 2 2 6
Lowell, MA 26 19 6 1 — — 4 Norfolk, VA 64 43 13 4 — 4 2
Lynn, MA 12 10 1 1 — — 2 Richmond, VA 60 38 14 6 1 1 5
New Bedford, MA 22 17 3 2 — — 1 Savannah, GA 65 39 16 6 2 2 2
New Haven, CT 20 14 5 — 1 — — St. Petersburg, FL 49 31 12 3 1 2 4
Providence, RI 72 50 14 7 — 1 4 Tampa, FL 218 141 57 11 8 1 6
Somerville, MA 1 1 — — — — — Washington, D.C. 116 67 33 7 9 — 13
Springfield, MA 32 24 7 — — 1 3 Wilmington, DE 10 5 5 — — — —
Waterbury, CT 30 22 6 2 — — 3 E.S. Central 844 560 200 42 24 17 62
Worcester, MA 45 26 16 2 — 1 6 Birmingham, AL 150 101 31 10 3 5 15
Mid. Atlantic 1,770 1,242 389 92 23 23 99 Chattanooga, TN 89 57 19 7 4 2 3
Albany, NY 38 27 5 3 — 3 2 Knoxville, TN 96 77 14 1 3 1 2
Allentown, PA 24 17 3 3 1 — 1 Lexington, KY 64 41 17 3 1 2 5
Buffalo, NY 70 51 15 2 1 1 8 Memphis, TN 146 84 49 7 6 — 13
Camden, NJ 25 14 8 — 1 2 1 Mobile, AL 104 81 15 5 1 2 10
Elizabeth, NJ 21 13 7 1 — — 3 Montgomery, AL 34 23 9 — — 2 3
Erie, PA 45 33 8 4 — — 1 Nashville, TN 161 96 46 9 6 3 11
Jersey City, NJ 25 17 7 — 1 — 4 W.S. Central 1,163 713 306 76 30 38 75
New York City, NY 1,007 719 215 49 12 12 45 Austin, TX 92 63 19 4 2 4 9
Newark, NJ 34 19 10 4 1 — 1 Baton Rouge, LA 76 34 14 10 13 5 —
Paterson, NJ 20 13 5 1 — 1 1 Corpus Christi, TX 64 43 8 9 2 2 1
Philadelphia, PA 171 108 44 11 5 2 9 Dallas, TX 194 103 63 13 5 10 15
Pittsburgh, PA§ 30 23 5 — 1 1 3 El Paso, TX 67 53 11 3 — — 6
Reading, PA 23 20 2 1 — — — Fort Worth, TX U U U U U U U
Rochester, NY 72 46 20 5 — 1 10 Houston, TX 150 80 47 10 1 12 5
Schenectady, NY 11 9 1 1 — — 2 Little Rock, AR 52 31 17 4 — — 2
Scranton, PA 29 19 8 2 — — 2 New Orleans, LA U U U U U U U
Syracuse, NY 67 55 9 3 — — 5 San Antonio, TX 267 179 67 14 5 2 14
Trenton, NJ 29 17 11 1 — — — Shreveport, LA 52 26 21 3 1 1 6
Utica, NY 15 11 3 1 — — 1 Tulsa, OK 149 101 39 6 1 2 17
Yonkers, NY 14 11 3 — — — — Mountain 1,101 752 237 57 31 23 70
E.N. Central 2,060 1,381 488 113 45 33 113 Albuquerque, NM 128 98 23 4 1 2 17
Akron, OH 55 28 18 4 3 2 5 Boise, ID 49 39 9 1 — — 4
Canton, OH 41 31 9 1 — — 4 Colorado Springs, CO 60 41 11 6 2 — 3
Chicago, IL 238 152 55 23 8 — 13 Denver, CO 81 49 23 5 3 1 3
Cincinnati, OH 92 58 24 1 2 7 10 Las Vegas, NV 258 181 61 7 8 1 15
Cleveland, OH 288 206 67 8 4 3 16 Ogden, UT 25 21 2 1 1 — 3
Columbus, OH 170 124 31 7 5 3 13 Phoenix, AZ 169 90 48 13 10 7 8
Dayton, OH 136 101 26 6 2 1 7 Pueblo, CO 37 26 7 1 2 1 1
Detroit, MI 206 114 67 16 7 2 4 Salt Lake City, UT 104 73 20 8 1 2 12
Evansville, IN 52 40 9 2 1 — — Tucson, AZ 190 134 33 11 3 9 4
Fort Wayne, IN 67 50 12 3 — 2 3 Pacific 1,663 1,123 389 91 29 29 160
Gary, IN 19 8 6 3 1 1 — Berkeley, CA 16 11 2 2 1 — 1
Grand Rapids, MI 51 34 13 2 — 2 1 Fresno, CA 123 78 23 15 4 3 10
Indianapolis, IN 192 113 61 13 4 1 13 Glendale, CA 32 27 4 1 — — 7
Lansing, MI 42 29 8 4 1 — 2 Honolulu, HI 47 31 12 2 2 — 8
Milwaukee, WI 112 73 25 7 3 4 6 Long Beach, CA 71 41 24 4 1 1 8
Peoria, IL 39 30 3 4 1 1 1 Los Angeles, CA 265 152 86 17 8 2 31
Rockford, IL 48 37 6 2 2 1 1 Pasadena, CA 18 11 5 1 — 1 3
South Bend, IN 38 29 8 — — 1 3 Portland, OR 130 94 28 5 2 1 7
Toledo, OH 106 72 27 6 1 — 7 Sacramento, CA 208 152 41 8 3 4 23
Youngstown, OH 68 52 13 1 — 2 4 San Diego, CA 155 111 32 9 1 2 15
W.N. Central 545 356 125 33 13 18 44 San Francisco, CA 100 61 27 3 1 6 18
Des Moines, IA 61 48 9 2 2 — 6 San Jose, CA 179 129 37 8 4 1 16
Duluth, MN 21 17 4 — — — — Santa Cruz, CA 30 18 9 3 — — 1
Kansas City, KS 24 11 8 3 2 — 3 Seattle, WA 107 69 25 8 1 4 6
Kansas City, MO 90 58 21 5 — 6 5 Spokane, WA 60 47 11 2 — — 1
Lincoln, NE 34 30 4 — — — 1 Tacoma, WA 122 91 23 3 1 4 5
Minneapolis, MN 72 38 21 8 2 3 4 Total¶ 10,950 7,272 2,618 604 239 212 739
Omaha, NE 102 71 24 3 2 2 13
St. Louis, MO 22 7 4 5 3 3 2
St. Paul, MN 49 30 16 3 — — 6
Wichita, KS 70 46 14 4 2 4 4
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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